
  
    
      
        Background_NNP
        The_DT 
        hedgehog_NN (_( 
        hh_NN )_) gene_NN was_VBD identified_VBN two_CD decades_NNS
        ago_RB in_IN 
        Drosophila_NNP as_IN a_DT critical_JJ regulator_NN of_IN
        cell-fate_JJ determination_NN during_IN embryogenesis_NNS [_NN 1_CD ]_NN ._.
        Subsequent_JJ work_NN in_IN several_JJ model_NN systems_NNS has_VBZ defined_VBN and_CC
        characterized_VBD the_DT 
        Hh_NNP gene_NN family_NN that_IN encodes_NNS highly_RB
        conserved_JJ secreted_JJ signaling_VBG proteins_NNS (_( for_IN review_NN see_VB [_NN 2_CD ]_NN
        )_) ._. Hedgehog_NNP (_( Hh_NNP )_) proteins_NNS are_VBP synthesized_JJ as_IN approximately_RB
        45_CD kDa_NN precursors_NNS that_IN autoprocess_NNS in_IN an_DT unprecedented_JJ
        fashion_NN ,_, resulting_VBG in_IN the_DT covalent_NN attachment_NN of_IN a_DT
        cholesterol_NN moiety_NN to_TO the_DT amino-terminal_JJ half_NN of_IN the_DT
        precursor_NN [_NN 2_CD ]_NN ._. This_DT processed_VBN amino-terminal_JJ domain_NN ,_,
        Hh-_NNP Np_NNP ,_, is_VBZ responsible_JJ for_IN the_DT activation_NN of_IN a_DT unique_JJ and_CC
        complex_NN signaling_VBG cascade_NN that_WDT is_VBZ essential_JJ for_IN controlling_VBG
        cell_NN fate_NN throughout_IN development_NN and_CC into_IN adulthood_NN [_NN 2_CD ]_NN ._.
        In_IN mammals_NNS there_RB are_VBP three_CD Hh-family_NNP proteins_NNS :_: Sonic_NNP (_( Shh_NNP )_) ,_,
        Indian_JJ (_( Ihh_NNP )_) ,_, and_CC Desert_NNP (_( Dhh_NNP )_) ._. Gene-targeting_NNP experiments_NNS
        in_IN mice_NNS have_VBP demonstrated_VBN that_IN the_DT development_NN and_CC
        patterning_VBG of_IN essentially_RB every_DT major_JJ organ_NN requires_VBZ input_NN
        from_IN the_DT Hh_NNP pathway_NN [_NN 2_CD ]_NN ._.
        
        In_IN vitro_NN culture_NN systems_NNS of_IN neuronal_NN
        tissues_NNS have_VBP been_VBN used_VBN to_TO characterize_VB the_DT biology_NN of_IN the_DT
        Hh-signaling_NNP pathway_NN ._. Most_JJS notably_RB ,_, the_DT neural-plate_JJ
        explant_NN assay_NN has_VBZ defined_VBN the_DT concentration-dependent_JJ role_NN
        that_IN ventrally_RB expressed_VBD Shh_NNP plays_VBZ in_IN opposing_VBG dorsally_RB
        expressed_VBD bone_NN morphogenetic_JJ proteins_NNS (_( BMPs_NNP )_) to_TO pattern_NN the_DT
        neural_NN tube_NN [_NN 2_CD ]_NN ._. The_DT assay_NN demonstrates_VBZ that_IN the_DT
        Hh-signaling_NNP cascade_NN can_MD distinguish_VB between_IN small_JJ
        concentration_NN differences_NNS in_IN the_DT Hh_NNP ligand_NN to_TO instruct_VB the_DT
        differentiation_NN of_IN specific_JJ neuronal_NN cell_NN types_NNS ._. Additional_JJ
        insights_NNS have_VBP been_VBN gained_VBN by_IN utilizing_VBG cultures_NNS of_IN
        postnatal_NN cerebellar_NN neuron_NN precursors_NNS [_NN 2_CD ]_NN ._. These_DT
        studies_NNS have_VBP shown_VBN that_IN Hh_NNP patterns_NNS the_DT cerebellum_NN by_IN
        promoting_VBG proliferation_NN of_IN the_DT granule_NN neuron_NN precursors_NNS ._.
        Given_VBN the_DT role_NN that_IN Hh_NNP signaling_VBG plays_VBZ in_IN promoting_VBG
        progenitor-cell_JJ proliferation_NN ,_, it_PRP is_VBZ not_RB surprising_JJ that_DT
        misregulation_NN of_IN Hh_NNP signaling_VBG has_VBZ been_VBN implicated_VBN in_IN the_DT
        biology_NN of_IN certain_JJ cancers_NNS ,_, in_IN particular_JJ basal_NN cell_NN
        carcinoma_NN (_( BCC_NNP )_) and_CC medulloblastoma_NN ._.
        The_DT Hh-signaling_NNP pathway_NN comprises_VBZ three_CD main_JJ
        components_NNS :_: the_DT Hh_NNP ligand_NN ;_: a_DT transmembrane_NN receptor_NN circuit_NN
        composed_VBN of_IN the_DT negative_JJ regulator_NN Patched_NNP (_( Ptc_NNP )_) plus_CC an_DT
        activator_NN ,_, Smoothened_NNP (_( Smo_NNP )_) ;_: and_CC finally_RB a_DT cytoplasmic_JJ
        complex_NN that_WDT regulates_VBZ the_DT Cubitus_NNP interruptus_JJ (_( Ci_NNP )_) or_CC Gli_NNP
        family_NN of_IN transcriptional_NN effectors_NNS ._. Additional_JJ pathway_NN
        components_NNS are_VBP thought_VBN to_TO modulate_VBP the_DT activity_NN or_CC
        subcellular_NN distribution_NN of_IN these_DT molecules_NNS [_NN 2_CD ]_NN ._. There_EX
        is_VBZ positive_JJ and_CC negative_JJ feedback_NN at_IN the_DT transcriptional_NN
        level_NN as_IN the_DT 
        Gli_NNP 1_CD and_CC 
        Ptc_NNP 1_CD genes_NNS are_VBP direct_JJ transcriptional_NN
        targets_NNS of_IN activation_NN of_IN the_DT pathway_NN ._.
        Smo_NNP is_VBZ a_DT seven-pass_JJ transmembrane_NN protein_NN with_IN homology_NN
        to_TO G-_NNP protein-coupled_JJ receptors_NNS (_( GPCRs_NNP )_) ,_, while_IN Ptc_NNP is_VBZ a_DT
        twelve-pass_JJ transmembrane_NN protein_NN that_WDT resembles_VBZ a_DT channel_NN
        or_CC transporter_NN ._. Consistent_NNP with_IN its_PRP$ role_NN as_IN an_DT essential_JJ
        pathway_NN inhibitor_NN ,_, removal_NN of_IN Ptc_NNP renders_NNS the_DT Hh_NNP pathway_NN
        constitutively_RB '_POS on_IN '_POS ,_, independent_JJ of_IN the_DT Hh_NNP ligand_NN ._.
        Similarly_RB ,_, specific_JJ point_NN mutations_NNS in_IN the_DT transmembrane_NN
        helices_NNS of_IN Smo_NNP are_VBP capable_JJ of_IN constitutively_RB stimulating_VBG
        the_DT pathway_NN ,_, effectively_RB bypassing_VBG Ptc_NNP inhibition_NN [_NN 3_CD ]_NN ._.
        At_IN present_JJ ,_, a_DT controversy_NN surrounds_NNS the_DT mechanism_NN by_IN which_WDT
        Ptc_NNP inhibits_NNS Smo_NNP ._. Although_IN early_JJ studies_NNS suggested_VBD a_DT
        simple_JJ ,_, direct_JJ ,_, stoichiometric_JJ regulation_NN ,_, more_RBR recent_JJ data_NNS
        support_VBP a_DT more_RBR complicated_JJ indirect_JJ or_CC catalytic_JJ model_NN [_NN 2_CD
        ]_NN ._. And_CC although_IN it_PRP has_VBZ been_VBN demonstrated_VBN that_IN Hh_NNP directly_RB
        interacts_NNS with_IN [_NN 4_CD ]_NN and_CC destabilizes_NNS [_NN 5_CD ]_NN Ptc_NNP ,_, the_DT
        downstream_JJ molecular_JJ events_NNS remain_VBP obscure_JJ ._. In_IN particular_JJ ,_,
        little_JJ is_VBZ known_VBN about_IN the_DT means_NNS by_IN which_WDT Ptc_NNP exerts_NNS its_PRP$
        inhibitory_NN effect_NN on_IN Smo_NNP ,_, or_CC how_WRB Smo_NNP communicates_NNS with_IN the_DT
        cytoplasmic_JJ Ci_NNP /_NN Gli_NNP transcription_NN factor_NN complex_JJ ._.
        Through_IN a_NNP '_POS chemical_NN genetic_JJ '_POS approach_NN of_IN identifying_VBG and_CC
        studying_VBG the_DT mechanism_NN of_IN action_NN of_IN small-molecule_JJ agonists_NNS
        (_( and_CC antagonists_NNS )_) ,_, we_PRP hoped_VBD to_TO uncover_VB some_DT of_IN the_DT
        complexities_NNS of_IN the_DT Hh-signaling_NNP system_NN ._. Small-molecule_NNP
        modulators_NNS of_IN growth-factor_JJ pathways_NNS have_VBP proven_VBN valuable_JJ
        in_IN providing_VBG enhanced_JJ understanding_NN of_IN the_DT intracellular_NN
        events_NNS that_WDT occur_VBP subsequent_JJ to_TO receptor_NN activation_NN ,_, and_CC in_IN
        establishing_VBG the_DT biological_JJ functions_NNS of_IN these_DT pathways_NNS [_NN 6_CD
        7_CD 8_CD ]_NN ._. In_IN Hh_NNP signaling_VBG ,_, multiple_JJ insights_NNS have_VBP been_VBN gained_VBN
        through_IN the_DT use_NN of_IN the_DT plant-derived_JJ Hh_NNP antagonist_NN
        cyclopamine_NN [_NN 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD ]_NN and_CC a_DT recently_RB
        identified_VBN synthetic_JJ small-molecule_JJ Hh-signaling_NNP inhibitor_NN ,_,
        Cur_NNP 61414_CD [_NN 17_CD ]_NN ._. Interestingly_RB ,_, these_DT specific_JJ inhibitors_NNS
        of_IN Hh_NNP signaling_VBG appear_VB to_TO function_VB downstream_JJ of_IN Ptc_NNP but_CC
        their_PRP$ precise_JJ molecular_JJ target_NN (_( s_VBZ )_) and_CC mechanism_NN of_IN action_NN
        are_VBP unknown_JJ ._.
        Although_IN genetic_JJ manipulations_NNS involving_VBG
        gain-of-function_JJ point_NN mutations_NNS of_IN Smo_NNP [_NN 3_CD ]_NN have_VBP
        demonstrated_VBN that_IN the_DT pathway_NN can_MD be_VB activated_VBN
        independently_RB of_IN Hh_NNP ligand_NN ,_, no_DT small_JJ molecules_NNS with_IN this_DT
        capability_NN have_VBP been_VBN identified_VBN ._. Indeed_RB ,_, it_PRP has_VBZ proven_VBN
        difficult_JJ to_TO identify_VB small-molecule_JJ agonists_NNS of_IN any_DT
        signaling_VBG pathway_NN activated_VBN by_IN a_DT protein_NN ligand_NN ._. Two_CD
        examples_NNS have_VBP recently_RB been_VBN described_VBN ,_, however_RB ._. One_CD
        involved_VBN identification_NN of_IN a_DT non-peptide_JJ activator_NN of_IN the_DT
        granulocyte_NN colony-stimulating_JJ factor_NN (_( GCSF_NNP )_) pathway_NN that_WDT
        appeared_VBD to_TO act_VB via_IN receptor_NN oligomerization_NN [_NN 18_CD ]_NN ._.
        Another_DT report_NN described_VBD a_DT small-molecule_JJ activator_NN of_IN the_DT
        insulin-signaling_JJ pathway_NN that_IN also_RB acts_VBZ at_IN the_DT level_NN of_IN
        the_DT receptor_NN [_NN 19_CD ]_NN ._.
        Since_IN the_DT Hh_NNP receptor_NN ,_, Ptc_NNP ,_, serves_VBZ to_TO inhibit_VB signaling_VBG ,_,
        a_DT small-molecule_JJ pathway_NN activator_NN would_MD need_VB to_TO be_VB capable_JJ
        of_IN one_CD of_IN the_DT following_VBG :_: first_JJ ,_, interfering_VBG with_IN the_DT
        inhibitory_NN effect_NN that_IN Ptc_NNP exerts_NNS on_IN Smo_NNP ;_: second_JJ ,_,
        activating_VBG Smo_NNP without_IN affecting_VBG Ptc_NNP ;_: or_CC third_JJ ,_, activating_VBG
        the_DT pathway_NN downstream_JJ of_IN Smo_NNP ._. Identifying_NNP small_JJ molecules_NNS
        with_IN any_DT of_IN these_DT activities_NNS would_MD provide_VB useful_JJ
        information_NN concerning_VBG the_DT details_NNS of_IN Hh_NNP signaling_VBG and_CC
        would_MD also_RB provide_VB a_DT simple_JJ means_NNS of_IN modulating_VBG activity_NN of_IN
        the_DT pathway_NN 
        in_IN vivo_NN or_CC 
        in_IN vitro_NN ._.
        In_IN this_DT article_NN ,_, we_PRP show_VBP that_IN a_DT non-peptidyl_JJ
        small-molecule_JJ agonist_NN of_IN Hh_NNP signaling_VBG has_VBZ been_VBN identified_VBN
        that_WDT has_VBZ all_PDT the_DT known_VBN signaling_VBG properties_NNS of_IN the_DT
        recombinant_JJ Hh_NNP protein_NN ._. But_CC this_DT agonist_NN ,_, unlike_IN Hh_NNP
        protein_NN ,_, appears_VBZ to_TO bypass_VB the_DT Ptc-regulatory_NNP step_NN ,_, by_IN
        interacting_VBG directly_RB with_IN Smo_NNP ._. Furthermore_RB ,_, studies_NNS with_IN
        the_DT agonist_NN and_CC several_JJ antagonists_NNS of_IN Hh_NNP signaling_VBG suggest_VBP
        that_IN Smo_NNP can_MD be_VB activated_VBN or_CC inhibited_VBD by_IN direct_JJ
        interaction_NN with_IN small-molecule_JJ ligands_NNS ._. These_DT observations_NNS
        suggest_VBP that_IN the_DT Ptc-_NNP Smo_NNP receptor_NN circuit_NN may_MD incorporate_VB
        native_JJ small-molecule_JJ ligands_NNS in_IN the_DT regulation_NN of_IN Hh_NNP
        signaling_VBG ._.
      
      
        Results_NNS
        
          Isolation_NNP of_IN Hh_NNP agonists_NNS by_IN high-throughput_JJ
          screening_NN
          To_TO identify_VB small-molecule_JJ agonists_NNS of_IN Hh_NNP signaling_VBG ,_,
          we_PRP established_VBD a_DT mammalian-cell-based_JJ assay_NN ._. After_IN
          testing_NN several_JJ cell_NN lines_NNS for_IN Hh-dependent_NNP induction_NN of_IN
          the_DT target_NN genes_NNS 
          Ptc_NNP 1_CD and_CC 
          Gli_NNP 1_CD [_NN 2_CD ]_NN ,_, we_PRP identified_VBD
          C_NNP 3_CD H_NNP 10_CD T_NN 1_CD /_NN 2_CD and_CC TM_NNP 3_CD cells_NNS as_IN optimal_NN responders_NNS ._. We_PRP then_RB
          introduced_VBD into_IN each_DT line_NN a_DT plasmid_NN containing_VBG a_DT
          luciferase_NN reporter_NN downstream_JJ of_IN multimerized_JJ Gli_NNP
          binding_JJ sites_NNS and_CC a_DT minimal_JJ promoter_NN [_NN 20_CD ]_NN ._. An_DT isolated_VBN
          stable_JJ clone_NN of_IN the_DT 10_CD T_NN 1_CD /_NN 2_CD cell_NN transfectants_NNS (_( referred_VBD
          to_TO as_IN clone_NN S_NNP 12_CD )_) gave_VBD a_DT 10_CD -_: 20_CD -_: fold_VB up-regulation_JJ of_IN
          luciferase_NN activity_NN (_( Figure_NN 1_CD a_DT )_) when_WRB stimulated_VBN with_IN Hh_NNP
          protein_NN [_NN 21_CD ]_NN for_IN 24_CD hours_NNS ._. Using_VBG this_DT assay_NN system_NN ,_, we_PRP
          screened_VBD 140_CD ,_, 000_CD synthetic_JJ compounds_NNS at_IN a_DT concentrations_NNS
          of_IN 2_CD -_: 5_CD μM_NN and_CC isolated_VBN several_JJ putative_JJ agonists_NNS ._. One_CD of_IN
          these_DT molecules_NNS -_: Hh-_NNP Ag_NNP 1_CD ._. 1_CD (_( Figure_NN 1_CD a_DT ,_, b_SYM )_) -_: was_VBD studied_VBN
          further_RB ._. Hh-_NNP Ag_NNP 1_CD ._. 1_CD exhibited_VBN half-maximal_JJ stimulation_NN (_( EC_NNP
          
          50_CD )_) at_IN around_IN 3_CD μM_NN ,_, and_CC an_DT activation_NN
          maximum_NN (_( A_DT 
          max_NN )_) of_IN approximately_RB 35_CD %_NN compared_VBN to_TO
          the_DT Hh_NNP protein_NN control_NN (_( Figure_NN 1_CD a_DT )_) ._. In_IN the_DT presence_NN of_IN
          sub-threshold_JJ signaling_VBG levels_NNS of_IN Hh_NNP protein_NN (_( 0_CD ._. 3_LS nM_NN )_) ,_,
          the_DT EC_NNP 
          50_CD of_IN Hh-_NNP Ag_NNP 1_CD ._. 1_CD was_VBD reduced_VBN to_TO around_IN
          0_CD ._. 4_CD μM_NN and_CC the_DT A_DT 
          max_NN approached_VBD 70_CD %_NN (_( Figure_NN 1_CD a_DT )_) ._.
          We_PRP next_RB tested_VBN whether_IN expression_NN of_IN endogenous_JJ
          Hh-responsive_NNP genes_NNS was_VBD stimulated_VBN by_IN the_DT agonist_NN ._. Using_VBG
          quantitative_JJ PCR_NNP ,_, Hh-_NNP Ag_NNP 1_CD ._. 1_CD was_VBD shown_VBN clearly_RB to_TO elevate_NN
          the_DT expression_NN of_IN 
          Gli_NNP 1_CD and_CC 
          Ptc_NNP 1_CD in_IN a_DT dose-dependent_JJ manner_NN
          (_( Figure_NN 1_CD c_SYM )_) ._.
        
        
          Chemical_NN modifications_NNS increase_VBP potency_NN
          In_IN an_DT effort_NN to_TO improve_VB the_DT potency_NN of_IN Hh-_NNP Ag_NNP 1_CD ._. 1_CD ,_, over_IN
          300_CD derivatives_NNS were_VBD synthesized_JJ and_CC tested_VBN in_IN the_DT
          cell-based_JJ reporter_NN assay_NN ._. The_DT relative_JJ potencies_NNS of_IN the_DT
          most_RBS active_JJ derivatives_NNS -_: 1_CD ._. 2_CD ,_, 1_CD ._. 3_CD ,_, 1_CD ._. 4_CD and_CC 1_CD ._. 5_CD -_: are_VBP
          shown_VBN in_IN Figure_NN 1_CD d_SYM ._. The_DT most_RBS potent_JJ ,_, Hh-_NNP Ag_NNP 1_CD ._. 5_CD ,_, had_VBD an_DT EC_NNP
          
          50_CD of_IN approximately_RB 1_CD nM_NN ._. Thus_RB ,_,
          potency_NN was_VBD increased_VBN over_IN 1000_CD -_: fold_VB by_IN chemical_NN
          modification_NN ._. The_DT structures_NNS of_IN compounds_NNS 1_CD ._. 2_CD and_CC 1_CD ._. 3_CD are_VBP
          shown_VBN in_IN Figure_NN 1_CD e_SYM ._. Hh-_NNP Ag_NNP 1_CD ._. 2_CD was_VBD the_DT most_RBS stable_JJ
          derivative_NN 
          in_IN vivo_NN and_CC 
          in_IN vitro_NN (_( data_NNS not_RB shown_VBN )_) and_CC was_VBD
          used_VBN for_IN most_JJS cell-based_JJ assays_NNS ._. Hh-_NNP Ag_NNP 1_CD ._. 3_CD showed_VBD lower_JJR
          toxicity_NN in_IN embryonic_JJ tissue_NN cultures_NNS (_( data_NNS not_RB shown_VBN )_)
          and_CC was_VBD used_VBN for_IN the_DT neural_NN plate_NN explant_NN assays_NNS
          described_VBD below_IN ._. These_DT experiments_NNS suggest_VBP that_IN the_DT
          agonist_NN may_MD have_VB many_JJ of_IN the_DT properties_NNS of_IN the_DT Hh_NNP ligand_NN ._.
          To_TO specifically_RB test_VB this_DT ,_, we_PRP used_VBD two_CD established_VBN 
          in_IN vitro_NN assay_NN systems_NNS that_WDT detect_VBP
          the_DT effects_NNS of_IN Hh_NNP on_IN primary_JJ neuronal_NN precursors_NNS ._.
        
        
          In_IN vitroassay_NN of_IN neuronal_NN precursors_NNS
          
            Proliferation_NNP activity_NN of_IN the_DT agonist_NN
            It_PRP has_VBZ recently_RB been_VBN shown_VBN that_IN primary_JJ neonatal_NN
            cerebellar_NN granule_NN neuron_NN (_( CGN_NNP )_) precursors_NNS proliferate_VBP
            in_IN response_NN to_TO Hh_NNP stimulation_NN [_NN 2_CD ]_NN ._. To_TO determine_VB
            whether_IN the_DT Hh_NNP agonist_NN could_MD elicit_NN this_DT response_NN ,_, we_PRP
            monitored_VBD [_NN 3_CD H_NNP ]_NN -_: thymidine_NN incorporation_NN of_IN cultured_JJ rat_NN
            CGN_NNP precursors_NNS treated_VBN with_IN Hh_NNP protein_NN ,_, Hh-_NNP Ag_NNP 1_CD ._. 1_CD ,_,
            Hh-_NNP Ag_NNP 1_CD ._. 2_CD ,_, or_CC vehicle_NN (_( DMSO_NNP )_) ._. The_DT original_JJ active_JJ
            molecule_NN ,_, Hh-_NNP Ag_NNP 1_CD ._. 1_CD ,_, stimulated_VBN thymidine_NN incorporation_NN
            at_IN 5_CD μM_NN ,_, but_CC not_RB at_IN 1_CD ._. 75_CD μM_NN (_( Figure_NN 1_CD f_SYM )_) ._. The_DT extent_NN of_IN
            proliferation_NN was_VBD around_IN 50_CD %_NN of_IN that_DT seen_VBN with_IN a_DT high_JJ
            dose_NN of_IN Hh_NNP protein_NN (_( 50_CD nM_NN )_) ._. Hh-_NNP Ag_NNP 1_CD ._. 2_CD stimulated_VBN
            proliferation_NN at_IN 300_CD nM_NN and_CC 100_CD nM_NN to_TO levels_NNS comparable_JJ
            to_TO those_DT seen_VBN with_IN Hh_NNP protein_NN (_( Figure_NN 1_CD f_SYM )_) ._. These_DT data_NNS
            demonstrate_VBP that_IN the_DT agonists_NNS can_MD elicit_NN a_DT biological_JJ
            response_NN in_IN primary_JJ cells_NNS similar_JJ to_TO that_DT produced_VBN by_IN
            Hh_NNP protein_NN ._.
          
          
            Morphogenic_NNP activity_NN of_IN the_DT agonist_NN
            Neural_NNP progenitors_NNS within_IN the_DT intermediate_JJ region_NN of_IN
            the_DT chick_NN neural_NN plate_NN (_( Figure_NN 2_CD a_DT )_) respond_NN to_TO
            increasing_VBG concentrations_NNS of_IN Hh_NNP protein_NN by_IN adopting_VBG
            specific_JJ fates_NNS ._. The_DT identity_NN of_IN these_DT cells_NNS can_MD be_VB
            assessed_VBN by_IN their_PRP$ distinct_JJ expression_NN patterns_NNS of_IN a_DT set_NN
            of_IN transcription_NN factors_NNS [_NN 2_CD ]_NN ._. Three_CD of_IN these_DT
            transcription_NN factors_NNS -_: Pax_NNP 7_CD ,_, MNR_NNP 2_CD and_CC Nkx_NNP 2_CD ._. 2_LS -_: whose_WP$
            expression_NN is_VBZ differentially_RB sensitive_JJ to_TO increasing_VBG
            concentrations_NNS of_IN Hh_NNP protein_NN were_VBD assayed_JJ in_IN response_NN
            to_TO varying_VBG concentrations_NNS of_IN the_DT agonist_NN (_( Hh-_NNP Ag_NNP 1_CD ._. 3_LS )_) ._.
            The_DT dorsal_NN spinal_JJ cord_NN marker_NN Pax_NNP 7_CD is_VBZ normally_RB
            repressed_VBN by_IN low_JJ concentrations_NNS of_IN Hh_NNP [_NN 22_CD ]_NN ._. Pax_NNP 7_CD
            expression_NN was_VBD extinguished_JJ by_IN 1_CD -_: 10_CD nM_NN agonist_NN (_( Figure_NN
            2_CD b_SYM ,_, c_SYM ,_, d_SYM ,_, e_SYM ,_, f_SYM )_) ._. Higher_JJR concentrations_NNS of_IN agonist_NN (_( 10_CD -_: 200_CD
            nM_NN )_) induced_VBN expression_NN of_IN the_DT motor_NN neuron_NN progenitor_NN
            marker_NN MNR_NNP 2_CD (_( Figure_NN 2_CD b_SYM ,_, g_SYM ,_, h_NN ,_, i_NNP ,_, j_NN )_) ,_, and_CC yet_RB higher_JJR
            concentrations_NNS (_( 20_CD nM-_NN 1_CD μM_NN )_) induced_VBD the_DT most_JJS ventral_NN
            interneuron_NN progenitor_NN marker_NN Nkx_NNP 2_CD ._. 2_LS (_( Figure_NN
            2_CD b_SYM ,_, k_NN ,_, l_NN ,_, m_NN ,_, n_NN )_) ._. This_DT dose-dependent_JJ profile_NN of_IN expression_NN
            closely_RB resembles_VBZ the_DT response_NN achieved_VBN by_IN increasing_VBG
            concentrations_NNS of_IN Hh_NNP protein_NN [_NN 22_CD 23_CD 24_CD ]_NN ,_,
            demonstrating_VBG that_IN the_DT Hh_NNP agonist_NN mimics_VBZ the_DT
            concentration-dependent_JJ inductive_JJ activity_NN of_IN Hh_NNP on_IN
            neural_NN precursors_NNS ._.
          
        
        
          Activity_NN of_IN the_DT agonist_NN in_IN vivo_NN
          
            Agonist_NNP site_NN of_IN action_NN in_IN vivo_NN
            Having_VBG established_VBD an_DT 
            in_IN utero_NN assay_NN for_IN Hh_NNP signaling_VBG ,_,
            we_PRP next_RB investigated_VBN whether_IN the_DT agonist_NN could_MD rescue_VB
            aspects_NNS of_IN 
            Shh_NNP -_: or_CC 
            Smo_NNP -_: mutant_JJ phenotypes_NNS ,_, by_IN
            monitoring_VBG 
            lacZ_NN expression_NN in_IN 
            Smo_NNP -_: /_NN -_: 
            Ptc_NNP 1_CD 
            lacZ_NN /_NN +_NN embryos_NNS [_NN 26_CD ]_NN and_CC 
            Ptc_NNP 1_CD mRNA_NN levels_NNS in_IN 
            Shh_NNP -_: /_NN -_: embryos_NNS ._.
            Pregnant_NNP mice_NNS from_IN 
            Shh_NNP +_NN /_NN -_: and_CC 
            Smo_NNP +_NN /_NN -_: intercrosses_NNS were_VBD treated_VBN
            by_IN oral_JJ gavage_NN with_IN vehicle_NN or_CC agonist_NN (_( 15_CD mg_NN /_NN kg_NN )_) at_IN
            6_CD ._. 5_CD and_CC 7_CD ._. 5_CD dpc_NN ._. Embryos_NNP were_VBD collected_VBN at_IN 6_CD -_: 8_CD somite_NN
            stages_NNS (_( E_NNP 8_CD ._. 5_LS )_) when_WRB the_DT midline_NN defects_NNS are_VBP first_JJ
            detectable_JJ in_IN both_DT 
            Shh_NNP -_: /_NN -_: and_CC 
            Smo_NNP -_: /_NN -_: embryos_NNS ,_, but_CC prior_RB to_TO any_DT
            general_JJ retardation_NN of_IN growth_NN and_CC development_NN [_NN 26_CD 27_CD ]_NN
            ._. In_IN both_DT 
            Shh_NNP +_NN /_NN -_: and_CC 
            Smo_NNP +_NN /_NN -_: 
            Ptc_NNP 1_CD 
            lacZ_NN /_NN +_NN embryos_NNS ,_, 
            Ptc_NNP 1_CD was_VBD detected_VBN in_IN ventral_NN
            neural_NN tube_NN ,_, somites_NNS and_CC lateral_NN plate_NN mesoderm_NN (_( Figure_NN
            3_CD e_SYM ,_, i_NNP ,_, m_NN )_) ._. Treatment_NNP with_IN the_DT agonist_NN dramatically_RB
            enhanced_VBD and_CC expanded_VBD the_DT expression_NN of_IN 
            Ptc_NNP 1_CD in_IN these_DT heterozygous_JJ
            embryos_NNS (_( Figure_NN 3_CD f_SYM ,_, j_NN ,_, n_NN )_) ._. This_DT was_VBD consistent_JJ with_IN what_WP
            we_PRP have_VBP observed_VBN in_IN wild-type_JJ embryos_NNS (_( Figure_NN
            3_CD a_DT ,_, b_SYM ,_, c_SYM ,_, d_SYM )_) ._. It_PRP is_VBZ worth_JJ noting_VBG that_IN the_DT agonist-treated_JJ
            embryos_NNS exhibited_VBN overgrowth_NN of_IN the_DT headfolds_NNS and_CC
            hindbrain_NN ,_, reminiscent_NN of_IN 
            Ptc_NNP 1_CD -_: /_NN -_: embryos_NNS (_( compare_VB Figure_NN
            3_CD e_SYM ,_, mwith_NN 3_CD f_SYM ,_, n_NN )_) ._.
            
            Shh_NNP -_: /_NN -_: and_CC 
            Smo_NNP -_: /_NN -_: embryos_NNS at_IN this_DT stage_NN (_( 6_CD -_: 8_CD
            somites_NNS )_) started_VBD to_TO show_VB fused_JJ ventral_NN lips_NNS of_IN the_DT
            cephalic_JJ folds_NNS ,_, and_CC a_DT single_JJ continuous_JJ optic_JJ vesicle_NN ,_,
            indicating_VBG lack_NN of_IN a_DT clearly_RB defined_VBN midline_NN (_( red_JJ
            arrow_NN ,_, Figure_NN 3_CD g_SYM ,_, and_CC data_NNS not_RB shown_VBN )_) ._. As_IN expected_VBN ,_, 
            Ptc_NNP 1_CD expression_NN was_VBD not_RB detected_VBN
            in_IN the_DT ventral_NN neural_NN tube_NN of_IN the_DT vehicle-treated_JJ 
            Shh_NNP -_: /_NN -_: embryos_NNS (_( arrowhead_NN ,_, Figure_NN
            3_CD g_SYM )_) ,_, whereas_IN expression_NN was_VBD seen_VBN in_IN lateral_NN plate_NN
            mesoderm_NN and_CC weakly_RB in_IN somites_NNS (_( Figure_NN 3_CD g_SYM ,_, k_NN )_) ._. This_DT is_VBZ
            most_RBS likely_JJ due_NN to_TO Ihh_NNP signaling_VBG in_IN these_DT tissues_NNS [_NN 26_CD
            ]_NN ._. Both_DT Shh_NNP and_CC Ihh_NNP signaling_VBG were_VBD dependent_JJ on_IN Smo_NNP ,_,
            however_RB ,_, because_IN 
            Ptc_NNP 1_CD expression_NN could_MD not_RB be_VB
            detected_VBN in_IN 
            Smo_NNP -_: /_NN -_: embryos_NNS (_( Figure_NN 3_CD o_NN )_) ._.
            Following_VBG agonist_NN treatment_NN ,_, we_PRP observed_VBD that_IN the_DT
            neural_NN tube_NN and_CC somite_NN expression_NN of_IN 
            Ptc_NNP 1_CD in_IN 
            Shh_NNP -_: /_NN -_: embryos_NNS was_VBD greater_JJR than_IN
            vehicle-treated_JJ wild-type_JJ levels_NNS (_( compare_VB Figure_NN
            3_CD h_NN ,_, lwith_NN 3_CD e_SYM ,_, i_NNP )_) ._. The_DT midline_NN defects_NNS in_IN 
            Shh_NNP -_: /_NN -_: embryos_NNS were_VBD at_IN least_JJS
            partly_RB rescued_VBD by_IN agonist_NN treatment_NN (_( compare_VB Figure_NN
            3_CD gand_NN 3_CD h_NN ;_: red_JJ arrows_NNS )_) ._. Like_IN 
            Shh_NNP +_NN /_NN -_: embryos_NNS ,_, 
            Shh_NNP -_: /_NN -_: embryos_NNS had_VBD overgrown_NN
            headfolds_NNS after_IN administration_NN of_IN the_DT Hh_NNP agonist_NN
            (_( Figure_NN 3_CD fand_NN h_NN )_) ._. In_IN contrast_NN ,_, agonist_NN treatment_NN had_VBD no_DT
            detectable_JJ effect_NN on_IN either_DT morphology_NN or_CC 
            Ptc_NNP 1_CD expression_NN in_IN 
            Smo_NNP -_: /_NN -_: embryos_NNS (_( compare_VB Figure_NN
            3_CD oand_NN p_NN )_) ._. In_IN summary_NN ,_, these_DT studies_NNS demonstrate_VBP that_DT
            agonist_NN activity_NN 
            in_IN vivo_NN does_VBZ not_RB depend_VB upon_IN Shh_NNP ,_,
            but_CC that_IN Smo_NNP is_VBZ absolutely_RB required_VBN ._.
          
        
        
          Mechanism_NNP of_IN action_NN
          
            Chemical_NN epistasis_NNS studies_NNS
            We_PRP sought_VBD to_TO determine_VB the_DT level_NN at_IN which_WDT the_DT
            agonist_NN acts_NNS in_IN the_DT Hh_NNP pathway_NN ,_, in_IN cultured_JJ cell_NN
            assays_NNS ._. To_TO begin_VB addressing_VBG this_DT question_NN ,_, we_PRP used_VBD the_DT
            Hh_NNP reporter_NN cell_NN line_NN to_TO conduct_VB competition_NN
            experiments_NNS between_IN the_DT Hh_NNP agonist_NN and_CC known_VBN Hh-_NNP
            signaling_VBG antagonists_NNS that_WDT block_VBP the_DT pathway_NN at_IN
            different_JJ levels_NNS (_( Figure_NN 4_CD a_DT )_) ._. These_DT include_VBP :_: a_DT
            Hh-protein-blocking_NNP antibody_NN ,_, 5_CD E_NNP 1_CD [_NN 23_CD ]_NN ;_: a_DT natural_JJ
            product_NN derivative_JJ ,_, cyclopamine_NN [_NN 9_CD 10_CD ]_NN that_WDT has_VBZ
            recently_RB been_VBN shown_VBN to_TO act_VB downstream_JJ of_IN Ptc_NNP ,_, perhaps_RB
            at_IN the_DT level_NN of_IN Smo_NNP [_NN 11_CD ]_NN ;_: a_DT recently_RB identified_VBN
            synthetic_JJ small-molecule_JJ inhibitor_NN ,_, Cur_NNP 61414_CD ,_, which_WDT has_VBZ
            inhibitory_NN properties_NNS similar_JJ to_TO cyclopamine_NN [_NN 17_CD ]_NN ;_:
            and_CC forskolin_NN ,_, an_DT adenylate_NN cyclase_NN /_NN protein_NN kinase_NN A_DT
            activator_NN that_WDT is_VBZ thought_VBN to_TO block_VB Hh_NNP signaling_VBG by_IN
            stimulating_VBG degradation_NN of_IN members_NNS of_IN the_DT Gli_NNP family_NN of_IN
            transcriptional_NN activators_NNS [_NN 2_CD ]_NN ._.
            The_DT Hh-blocking_NNP antibody_NN 5_CD E_NNP 1_CD had_VBD no_DT effect_NN on_IN
            pathway_NN activation_NN by_IN the_DT agonist_NN (_( Figure_NN 4_CD b_SYM )_) ,_, while_IN
            forskolin_NN (_( Figure_NN 4_CD c_SYM )_) ,_, cyclopamine_NN (_( Figure_NN 4_CD d_SYM )_) and_CC
            Cur_NNP 61414_CD (_( Figure_NN 4_CD e_SYM )_) ,_, were_VBD all_DT inhibitory_NN ._. The_DT lack_NN of_IN
            inhibition_NN by_IN 5_CD E_NNP 1_CD eliminates_VBZ the_DT possibility_NN that_IN the_DT
            small_JJ molecule_NN agonist_NN activates_NNS signaling_VBG indirectly_RB
            via_IN stimulation_NN of_IN Hh_NNP expression_NN ._. Furthermore_RB ,_, this_DT
            supports_VBZ the_DT data_NNS showing_VBG that_IN the_DT agonist_NN can_MD activate_VBP
            signaling_VBG in_IN 
            Shh_NNP -_: /_NN -_: embryos_NNS (_( Figure_NN 3_LS )_) and_CC
            suggests_VBZ that_IN the_DT agonist_NN function_NN is_VBZ not_RB only_RB
            downstream_JJ of_IN the_DT Hh_NNP protein_NN but_CC also_RB independent_JJ of_IN
            the_DT endogenous_JJ Hh-signaling_NNP modulators_NNS ,_, Tout_NNP veloux_NN and_CC
            HIP_NNP ,_, that_DT act_NN via_IN the_DT Hh_NNP ligand_NN [_NN 2_CD ]_NN ._. The_DT competition_NN
            experiment_NN with_IN forskolin_NN showed_VBD identical_JJ inhibition_NN
            curves_NNS for_IN Hh_NNP protein_NN and_CC the_DT agonist_NN ,_, strongly_RB
            suggesting_VBG that_IN the_DT action_NN of_IN the_DT small_JJ molecule_NN is_VBZ
            upstream_RB of_IN the_DT protein-kinase-_JJ A-_NNP sensitive_JJ step_NN in_IN the_DT
            pathway_NN ._. In_IN contrast_NN ,_, the_DT competition_NN experiments_NNS with_IN
            cyclopamine_NN (_( Figure_NN 4_CD d_SYM )_) and_CC Cur_NNP 61414_CD (_( Figure_NN 4_CD e_SYM )_) showed_VBD
            that_IN Hh_NNP protein_NN and_CC the_DT agonist_NN differ_VB in_IN their_PRP$
            sensitivity_NN to_TO these_DT antagonists_NNS ._. Specifically_RB ,_, the_DT
            agonist_NN appears_VBZ somewhat_RB resistant_JJ to_TO the_DT inhibitory_NN
            effect_NN of_IN cyclopamine_NN and_CC Cur_NNP 61414_CD ._. Identical_NNP results_NNS
            were_VBD seen_VBN using_VBG the_DT slightly_RB less_RBR active_JJ
            cyclopamine-related_JJ natural_JJ compound_NN jervine_NN ,_, and_CC the_DT
            more_RBR potent_JJ synthetic_JJ derivative_NN of_IN cyclopamine_NN ,_,
            KAAD-cyclopamine_NNP (_( data_NNS not_RB shown_VBN )_) ._. These_DT results_NNS argue_VBP
            that_IN the_DT agonist_NN activates_NNS the_DT pathway_NN downstream_JJ of_IN
            the_DT Hh-_NNP Ptc_NNP interaction_NN while_IN cyclopamine_NN ,_, Cur_NNP 61414_CD and_CC
            the_DT agonist_NN may_MD act_VB at_IN a_DT similar_JJ level_NN in_IN the_DT
            Hh-signaling_NNP cascade_NN ._.
          
          
            Regulation_NNP of_IN Ptc_NNP and_CC Smo_NNP by_IN Hh_NNP protein_NN and_CC Hh_NNP
            agonist_NN
            Recent_JJ work_NN in_IN 
            Drosophila_NNP tissue_NN culture_NN has_VBZ
            shown_VBN that_IN endogenous_JJ Ptc_NNP and_CC Smo_NNP proteins_NNS are_VBP
            differentially_RB affected_VBN by_IN the_DT addition_NN of_IN Hh_NNP to_TO the_DT
            growth_NN medium_NN [_NN 5_CD ]_NN ._. Ptc_NNP was_VBD destabilized_JJ ,_, while_IN Smo_NNP
            accumulated_VBN following_VBG post-translational_JJ modification_NN ._.
            To_TO test_VB whether_IN similar_JJ phenomena_NNS occur_VBP in_IN mammalian_JJ
            cells_NNS with_IN Hh_NNP protein_NN and_CC agonist_NN ,_, we_PRP generated_VBD stable_JJ
            cell_NN lines_NNS expressing_VBG two_CD epitope-tagged_JJ proteins_NNS ,_, Ptc_NNP
            coupled_VBN to_TO green_JJ fluorescent_NN protein_NN ,_, Ptc-_NNP GFP_NNP ,_, and_CC Smo_NNP
            coupled_VBN to_TO a_DT fragment_NN of_IN influenza_NN hemagglutinin_NN ,_,
            HA-Smo_NNP ._. Figure_NN 5_CD ashows_NNS an_DT immunoprecipitation_NN
            (_( anti-_NN GFP_NNP )_) plus_CC protein_NN blot_NN (_( anti-_NN Ptc_NNP )_) analysis_NN of_IN
            extracts_NNS from_IN these_DT cells_NNS treated_VBN for_IN 4_CD ,_, 8_CD and_CC 24_CD hours_NNS
            with_IN vehicle_NN ,_, 25_CD nM_NN Hh_NNP protein_NN or_CC 0_CD ._. 2_CD μM_NN Hh_NNP agonist_NN
            (_( see_VB Figure_NN 1_CD e_SYM ;_: Hh-_NNP Ag_NNP 1_CD ._. 2_LS )_) ._. This_DT experiment_NN shows_VBZ that_IN
            Ptc-_NNP GFP_NNP appears_VBZ to_TO be_VB destabilized_JJ by_IN Hh_NNP protein_NN but_CC
            not_RB by_IN the_DT agonist_NN ._. Similar_JJ results_NNS were_VBD seen_VBN at_IN higher_JJR
            doses_NNS of_IN agonist_NN (_( up_IN to_TO 2_CD μM_NN )_) and_CC in_IN several_JJ
            independent_JJ lines_NNS (_( data_NNS not_RB shown_VBN )_) ._. These_DT data_NNS further_JJ
            support_NN the_DT idea_NN that_IN Hh_NNP protein_NN and_CC the_DT agonist_NN act_NN in_IN
            distinct_JJ ways_NNS to_TO stimulate_VB the_DT pathway_NN ._.
            Figure_NN 5_CD bshows_NNS an_DT immunoblot_NN (_( anti-_NN HA_NNP )_) of_IN total_JJ
            extracts_NNS from_IN HA-Smo-expressing_NNP cells_NNS treated_VBN for_IN 2_CD ,_, 5_CD ,_,
            8_CD and_CC 20_CD hours_NNS with_IN vehicle_NN ,_, 35_CD nM_NN Hh_NNP protein_NN or_CC 0_CD ._. 5_CD μM_NN
            Hh_NNP agonist_NN ._. In_IN contrast_NN to_TO the_DT results_NNS with_IN Ptc-_NNP GFP_NNP ,_,
            incubation_NN of_IN cells_NNS with_IN both_DT Hh_NNP protein_NN and_CC the_DT
            small-molecule_JJ agonist_NN resulted_VBD in_IN the_DT apparent_JJ
            accumulation_NN of_IN HA-Smo_NNP protein_NN after_IN 5_CD hours_NNS of_IN
            incubation_NN ._. To_TO test_VB whether_IN the_DT accumulation_NN of_IN HA-Smo_NNP
            in_IN response_NN to_TO Hh_NNP protein_NN or_CC the_DT agonist_NN required_VBD
            protein_NN synthesis_NN ,_, a_DT similar_JJ study_NN was_VBD performed_VBN in_IN the_DT
            presence_NN of_IN cycloheximide_NN (_( Figure_NN 5_CD c_SYM )_) ._. Under_IN these_DT
            conditions_NNS ,_, HA-Smo_NNP accumulation_NN was_VBD detectable_JJ 5_CD hours_NNS
            after_IN addition_NN of_IN either_DT Hh_NNP protein_NN or_CC the_DT agonist_NN
            (_( Figure_NN 5_CD c_SYM )_) ;_: this_DT result_NN argues_VBZ that_IN the_DT effect_NN of_IN Hh_NNP
            protein_NN and_CC the_DT agonist_NN on_IN HA-Smo_NNP levels_NNS does_VBZ not_RB
            require_VB new_JJ protein_NN synthesis_NN ._. Finally_RB ,_, with_IN increasing_VBG
            concentrations_NNS of_IN Hh_NNP protein_NN and_CC the_DT agonist_NN there_EX is_VBZ a_DT
            clear_JJ dose-dependent_JJ increase_NN of_IN HA-Smo_NNP levels_NNS (_( Figure_NN
            5_CD d_SYM )_) ._. These_DT effects_NNS on_IN epitope-tagged_JJ Smo_NNP protein_NN were_VBD
            observed_VBN in_IN multiple_JJ lines_NNS (_( data_NNS not_RB shown_VBN )_) ._. Taken_VBN
            together_RB ,_, these_DT data_NNS suggest_VBP that_IN Hh_NNP protein_NN and_CC the_DT
            agonist_NN share_NN the_DT ability_NN to_TO stabilize_VB Smo_NNP ,_, but_CC only_RB Hh_NNP
            protein_NN can_MD destabilize_VB Ptc_NNP ._. Yet_RB the_DT agonist_NN is_VBZ fully_RB
            capable_JJ of_IN activating_VBG the_DT full_JJ signaling_VBG pathway_NN ._.
          
        
        
          Testing_NNP Smo_NNP as_IN the_DT molecular_JJ target_NN
          
            Binding_NNP in_IN whole_JJ cells_NNS
            Our_PRP$ biochemistry_NN experiments_NNS (_( above_IN )_) show_NN that_IN the_DT
            agonist_NN modulates_NNS Smo_NNP levels_NNS ,_, and_CC thus_RB may_MD activate_VBP Hh_NNP
            signaling_VBG by_IN directly_RB binding_JJ Smo_NNP ._. To_TO explore_VB this_DT
            possibility_NN we_PRP tested_VBD whether_IN a_DT tritiated_JJ form_NN of_IN the_DT
            agonist_NN analog_NN Hh-_NNP Ag_NNP 1_CD ._. 5_CD could_MD form_VB a_DT complex_NN with_IN Smo_NNP ,_,
            when_WRB Smo_NNP is_VBZ transiently_RB overexpressed_JJ in_IN 293_CD T_NN cells_NNS ._.
            Figure_NN 6_CD ashows_NNS immunoprecipitable_JJ counts_NNS of_IN extracts_NNS
            from_IN cells_NNS incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 2_CD hours_NNS with_IN 5_CD nM_NN [_NN
            3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD either_CC in_IN the_DT absence_NN (_( columns_NNS 1_CD -_: 3_LS )_) or_CC
            presence_NN of_IN competitors_NNS (_( columns_NNS 4_CD -_: 9_CD )_) ._.
            Immunocomplexes_NNP from_IN untransfected_JJ control_NN and_CC
            β-adrenergic-receptor_JJ transfected_JJ cells_NNS did_VBD not_RB contain_VB
            significant_JJ counts_VBZ (_( Figure_NN 6_CD a_DT ,_, columns_NNS 1_CD ,_, 2_LS )_) ._.
            Immunocomplexes_NNP derived_VBD from_IN cells_NNS expressing_VBG Smo_NNP
            (_( Figure_NN 6_CD a_DT ,_, column_NN 3_LS )_) resulted_VBD in_IN the_DT recovery_NN of_IN
            approximately_RB 40_CD ,_, 000_CD of_IN the_DT 800_CD ,_, 000_CD added_VBD counts_VBZ ,_,
            however_RB ._. To_TO test_VB the_DT specificity_NN of_IN this_DT apparent_JJ
            Hh-_NNP Ag_NNP /_NN Smo_NNP complex_NN ,_, cells_NNS were_VBD incubated_JJ with_IN 5_CD μM_NN
            (_( 1000_CD -_: fold_VB molar_NN excess_JJ )_) of_IN unlabeled_JJ Hh_NNP Ag_NNP 1_CD ._. 5_CD or_CC an_DT
            unlabeled_JJ ,_, signaling-inactive_JJ but_CC structurally_RB similar_JJ
            compound_NN ,_, an_DT Hh-_NNP Ag_NNP 1_CD ._. 1_CD derivative_JJ that_WDT has_VBZ a_DT two-carbon_JJ
            linker_NN in_IN place_NN of_IN the_DT cyclohexane_NN ring_NN (_( Figure_NN 6_CD a_SYM ;_:
            Hh-_NNP Ag_NNP 1_CD ._. 5_CD ,_, column_NN 4_CD ;_: Hh-_NNP Ag_NNP control_NN ,_, column_NN 5_LS )_) ._. The_DT
            addition_NN of_IN the_DT unlabeled_JJ Hh-_NNP Ag_NNP 1_CD ._. 5_CD ,_, but_CC not_RB the_DT
            inactive_JJ Hh-_NNP Ag_NNP 1_CD ._. 1_CD derivative_JJ agonist_NN control_NN ,_, resulted_VBD
            in_IN the_DT complete_JJ absence_NN of_IN counts_NNS in_IN the_DT immunocomplex_NN ._.
            These_DT results_NNS suggest_VBP that_IN a_DT stable_JJ ,_, specific_JJ
            interaction_NN can_MD form_VB between_IN Smo_NNP and_CC the_DT Hh_NNP
            agonist_NN ._.
            It_PRP has_VBZ been_VBN shown_VBN that_IN the_DT Hh-pathway_NNP antagonists_NNS
            cyclopamine_NN and_CC Cur_NNP 61414_CD block_VB signaling_VBG in_IN a_DT
            Ptc-independent_NNP manner_NN [_NN 11_CD 17_CD ]_NN and_CC therefore_RB may_MD act_VB
            directly_RB on_IN Smo_NNP ._. Having_VBG established_VBD a_DT binding_JJ assay_NN for_IN
            a_DT small-molecule_JJ agonist_NN binding_JJ to_TO Smo-expressing_NNP
            cells_NNS ,_, we_PRP next_RB tested_VBN whether_IN the_DT Hh_NNP antagonists_NNS could_MD
            selectively_RB compete_VB out_IN binding_JJ of_IN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD ._. To_TO
            perform_VB theses_NNS studies_NNS ,_, Smo-overexpressing_NNP 293_CD T_NN cells_NNS
            were_VBD incubated_JJ for_IN 2_CD hours_NNS at_IN 37_CD °_NN C_NNP with_IN 5_CD nM_NN [_NN
            3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD in_IN the_DT presence_NN of_IN either_DT
            KAAD-cyclopamine_NNP at_IN 5_CD μM_NN (_( Figure_NN 6_CD a_DT ,_, column_NN 6_CD )_) ,_, the_DT
            related_VBN but_CC inactive_JJ plant_NN compound_NN tomatadine_NN at_IN 5_CD μM_NN
            (_( Figure_NN 6_CD a_SYM ;_: Antag_NNP control_NN 1_CD ,_, column_NN 7_CD )_) ,_, Cur_NNP 61414_CD at_IN 5_CD
            μM_NN (_( Figure_NN 6_CD a_DT ,_, column_NN 8_CD )_) ,_, or_CC a_DT related_VBN but_CC inactive_JJ
            Cur_NNP 61414_CD derivative_JJ (_( Figure_NN 6_CD a_SYM ;_: Antag_NNP control_NN 2_CD ,_, column_NN
            9_CD )_) at_IN 5_CD μM_NN ._. These_DT data_NNS show_VBP that_IN the_DT Hh-signaling_NNP
            inhibitors_NNS ,_, but_CC not_RB structurally_RB related_VBN inactive_JJ
            compounds_NNS ,_, can_MD significantly_RB compete_VB with_IN the_DT binding_VBG
            of_IN the_DT Hh_NNP agonist_NN to_TO Smo-expressing_NNP cells_NNS ._. This_DT
            supports_VBZ the_DT model_NN that_IN all_DT of_IN these_DT small-molecule_JJ
            modulators_NNS of_IN Hh_NNP signaling_VBG are_VBP direct_JJ ligands_NNS of_IN
            Smo_NNP ._.
            We_PRP next_RB asked_VBD whether_IN a_DT derivative_NN of_IN the_DT Hh_NNP agonist_NN
            carrying_VBG a_DT photoactivatable_JJ crosslinker_NN could_MD be_VB
            coupled_VBN directly_RB to_TO Smo_NNP ,_, to_TO facilitate_VB further_JJ
            biochemical_JJ characterization_NN of_IN the_DT binding_JJ site_NN ._. To_TO
            perform_VB this_DT experiment_NN we_PRP synthesized_JJ a_DT tritiated_JJ
            diazirine_NN derivative_NN of_IN Hh-_NNP Ag_NNP 1_CD ._. 2_CD with_IN an_DT EC_NNP 
            50_CD in_IN the_DT cell-based_JJ assay_NN of_IN 35_CD nM_NN
            (_( data_NNS not_RB shown_VBN )_) ._. We_PRP incubated_JJ this_DT compound_NN at_IN 0_CD ._. 5_CD μM_NN
            with_IN HA-Smo-_NNP or_CC control_NN ,_, GFP-transfected_NNP 293_CD T_NN cells_NNS and_CC
            subsequently_RB ultraviolet-irradiated_JJ them_PRP to_TO initiate_VB
            crosslinking_VBG ._. Fractionation_NNP by_IN SDS-polyacrylamide_NNP gel_NN
            electrophoresis_NNS and_CC autoradiography_NN of_IN the_DT resulting_VBG
            immunocomplexes_NNS from_IN these_DT cells_NNS showed_VBD crosslinking_VBG
            exclusively_RB to_TO HA-Smo_NNP ,_, but_CC with_IN an_DT efficiency_NN of_IN less_JJR
            than_IN 1_CD %_NN (_( data_NNS not_RB shown_VBN )_) ._. This_DT result_NN demonstrates_VBZ that_IN
            a_DT Hh-agonist_NNP derivative_NN can_MD be_VB covalently_RB crosslinked_JJ
            to_TO Smo_NNP in_IN living_VBG cells_NNS ._. More_RBR efficient_JJ crosslinkers_NNS are_VBP
            required_VBN to_TO extend_VB these_DT studies_NNS ,_, however_RB ._.
          
          
            Cell-free_NNP membrane-binding_JJ assays_NNS
            To_TO test_VB whether_IN the_DT Hh_NNP agonist_NN could_MD interact_NN with_IN
            Smo_NNP 
            in_IN vitro_NN ,_, we_PRP transiently_RB
            overexpressed_JJ murine_NN Smo_NNP ,_, murine_NN Ptc_NNP ,_, rat_NN β_NN 2_CD -_: adrenergic_JJ
            receptor_NN and_CC GFP_NNP in_IN 293_CD T_NN cells_NNS ,_, harvested_VBN membranes_NNS and_CC
            performed_VBD a_DT filtration_NN membrane-binding_JJ assay_NN in_IN a_DT
            96_CD -_: well_RB plate_NN with_IN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD added_VBD at_IN 2_CD nM_NN ._.
            Figure_NN 6_CD bshows_NNS a_DT bar_NN graph_NN of_IN the_DT bound_VBN counts_VBZ from_IN
            these_DT binding_JJ assays_NNS (_( murine_NN Smo_NNP ,_, column_NN 1_CD ;_: GFP_NNP ,_, column_NN
            2_CD ;_: βAR_NN ,_, column_NN 3_CD ;_: murine_NN Ptc_NNP 1_CD ,_, column_NN 4_CD ;_: and_CC a_DT
            no-membrane_JJ plate_NN control_NN ,_, column_NN 5_LS )_) ._. The_DT no-membrane_JJ
            control_NN (_( column_NN 5_LS )_) was_VBD included_VBN to_TO show_VB the_DT degree_NN of_IN
            non-specific_JJ binding_VBG to_TO the_DT filter-plate_JJ apparatus_NN ._. The_DT
            Smo-containing_NNP membranes_NNS (_( column_NN 1_LS )_) are_VBP the_DT only_JJ
            samples_NNS that_WDT exhibit_NN significant_JJ binding_JJ above_IN that_DT
            seen_VBN in_IN the_DT absence_NN of_IN membranes_NNS ._.
            To_TO assess_VB the_DT specificity_NN of_IN binding_JJ ,_, we_PRP repeated_VBD
            the_DT experiment_NN in_IN the_DT presence_NN and_CC absence_NN of_IN a_DT
            1000_CD -_: fold_VB molar_NN excess_NN of_IN unlabeled_JJ agonist_NN (_( 2_CD μM_NN )_) ._. The_DT
            addition_NN of_IN '_POS cold_JJ '_POS compound_NN completely_RB competed_VBD out_RP
            these_DT counts_VBZ (_( Figure_NN 6_CD c_SYM ,_, column_NN 1_CD compared_VBN to_TO column_NN
            2_LS )_) ._. To_TO control_VB for_IN this_DT observation_NN ,_, we_PRP added_VBD an_DT
            unlabeled_JJ ,_, inactive_JJ Hh_NNP agonist_NN to_TO the_DT binding_JJ assay_NN at_IN
            2_CD μM_NN (_( a_DT 1000_CD -_: fold_VB molar_NN excess_JJ )_) ._. This_DT compound_NN was_VBD
            unable_JJ to_TO compete_VB out_RP the_DT binding_JJ of_IN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD to_TO
            the_DT Smo-containing_NNP membranes_NNS (_( Figure_NN 6_CD c_SYM ,_, column_NN 3_LS )_) ._.
            These_DT results_NNS argue_VBP that_IN Smo_NNP and_CC the_DT agonist_NN form_NN a_DT
            specific_JJ complex_NN 
            in_IN vitro_NN ,_, as_IN predicted_VBN by_IN the_DT
            whole_JJ cell_NN /_NN immunocomplex_NN binding_JJ assay_NN (_( Figure_NN 6_CD a_DT )_) ._.
            Having_VBG established_VBD an_DT 
            in_IN vitro_NN binding_JJ assay_NN for_IN the_DT Hh_NNP
            agonist_NN to_TO Smo_NNP ,_, we_PRP next_RB tested_VBN whether_IN the_DT
            Ptc-independent_NNP Hh_NNP antagonists_NNS could_MD selectively_RB
            compete_VB with_IN the_DT interaction_NN ._. Binding_NNP was_VBD assayed_JJ in_IN
            the_DT presence_NN of_IN KAAD-cyclopamine_NNP at_IN 10_CD μM_NN (_( Figure_NN 6_CD c_SYM ,_,
            column_NN 4_LS )_) ,_, tomatadine_NN at_IN 10_CD μM_NN (_( Figure_NN 6_CD c_SYM ;_: Antag_NNP
            control_NN 1_CD ,_, column_NN 5_LS )_) ,_, Cur_NNP 61414_CD at_IN 10_CD μM_NN (_( Figure_NN 6_CD c_SYM ,_,
            column_NN 6_CD )_) ,_, or_CC the_DT inactive_JJ Cur_NNP 61414_CD derivative_JJ (_( Figure_NN
            6_CD c_SYM ;_: Antag_NNP control_NN 2_CD ,_, column_NN 7_CD )_) at_IN 10_CD μM_NN ._. These_DT data_NNS
            show_VBP that_IN the_DT Hh-signaling_NNP inhibitors_NNS ,_, but_CC not_RB
            structurally_RB related_VBN inactive_JJ compounds_NNS ,_, can_MD
            significantly_RB compete_VB with_IN the_DT binding_VBG of_IN the_DT Hh_NNP
            agonist_NN to_TO Smo_NNP membranes_NNS ._.
          
        
        
          Kinetics_NNP ,_, saturation_NN and_CC competition_NN binding_JJ
          analysis_NN
          Next_JJ ,_, we_PRP sought_VBD to_TO generate_VB association_NN ,_, dissociation_NN
          and_CC saturation-binding_JJ curves_NNS ,_, in_IN order_NN to_TO derive_VB
          affinity_NN constants_NNS for_IN the_DT interaction_NN of_IN the_DT Hh_NNP agonist_NN
          and_CC Smo_NNP ._. To_TO control_VB for_IN nonspecific_JJ binding_JJ we_PRP used_VBD
          either_CC Cur_NNP 61414_CD or_CC Hh-_NNP Ag_NNP 1_CD ._. 5_CD as_IN unlabeled_JJ competitors_NNS ._.
          Similar_JJ results_NNS were_VBD generated_VBN if_IN control_NN membranes_NNS (_( from_IN
          cells_NNS transfected_JJ with_IN GFP_NNP ,_, βAR_NN ,_, or_CC Ptc_NNP )_) were_VBD used_VBN to_TO
          define_VB the_DT non-specific_JJ level_NN (_( data_NNS not_RB shown_VBN )_) ._.
          First_LS ,_, we_PRP performed_VBD a_DT kinetic_JJ analysis_NN to_TO establish_VB
          the_DT reversibility_NN of_IN the_DT binding_JJ reaction_NN and_CC the_DT
          approximate_JJ incubation_NN time_NN required_VBN for_IN equilibrium_NN
          binding_JJ studies_NNS ._. Association_NN assays_NNS were_VBD performed_VBN at_IN
          37_CD °_NN C_NNP by_IN combining_VBG 2_CD nM_NN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD with_IN
          Smo-containing_NNP membranes_NNS for_IN various_JJ times_NNS prior_RB to_TO
          harvesting_NN and_CC counting_VBG ._. Dissociation_NNP studies_NNS were_VBD
          initiated_VBN by_IN adding_VBG 2_CD μM_NN unlabeled_JJ Hh-_NNP Ag_NNP 1_CD ._. 5_CD after_IN 2_CD
          hours_NNS of_IN association_NN ._. Samples_NNP were_VBD then_RB incubated_JJ for_IN
          1_CD -_: 26_CD hours_NNS prior_RB to_TO harvesting_NN and_CC counting_VBG ._. Figure_NN
          7_CD ashows_NNS the_DT association_NN and_CC dissociation_NN phases_NNS of_IN
          agonist_NN binding_JJ to_TO Smo-containing_NNP membranes_NNS ._. Using_VBG the_DT
          Prism_NNP GraphPad_NNP software_NN ,_, these_DT data_NNS were_VBD fit_VBN to_TO one-phase_JJ
          exponential_NN association_NN and_CC decay_NN curves_NNS ,_, respectively_RB ,_,
          and_CC gave_VBD an_DT association_NN t_NN½ of_IN approximately_RB 1_CD hour_NN and_CC a_DT
          dissociation_NN t_NN½ of_IN approximately_RB 10_CD hours_NNS ._. These_DT results_NNS
          demonstrate_VBP that_IN the_DT binding_VBG of_IN the_DT agonist_NN to_TO Smo_NNP is_VBZ
          reversible_JJ and_CC that_DT equilibrium_NN binding_JJ will_MD require_VB
          binding_JJ reaction_NN times_NNS of_IN approximately_RB 50_CD hours_NNS (_( five_CD
          times_NNS the_DT t_NN½ of_IN dissociation_NN )_) ._.
          Next_JJ ,_, we_PRP performed_VBD a_DT saturation_NN binding_JJ experiment_NN ._. To_TO
          establish_VB total_JJ ,_, nonspecific_JJ ,_, and_CC specific_JJ binding_JJ curves_NNS
          (_( Figure_NN 7_CD b_SYM )_) ,_, we_PRP added_VBD a_DT range_NN of_IN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD
          concentrations_NNS (_( 0_CD ._. 01_CD -_: 3_CD nM_NN )_) in_IN the_DT presence_NN or_CC absence_NN of_IN
          unlabeled_JJ Hh-_NNP Ag-_NNP 1_CD ._. 5_LS at_IN 2_CD μM_NN ._. Identical_NNP results_NNS were_VBD seen_VBN
          if_IN Cur_NNP 61414_CD at_IN 10_CD μM_NN was_VBD used_VBN as_IN the_DT competitor_NN (_( data_NNS not_RB
          shown_VBN )_) ._. On_IN the_DT basis_NN of_IN the_DT binding_JJ kinetics_NNS ,_, incubations_NNS
          were_VBD carried_VBN out_IN for_IN approximately_RB 45_CD hours_NNS at_IN 37_CD °_NN C_NNP ,_, to_TO
          allow_VB for_IN equilibrium_NN to_TO be_VB reached_VBN ._. Using_VBG the_DT Prism_NNP
          GraphPad_NNP software_NN to_TO perform_VB non-linear_JJ regression_NN
          analysis_NN and_CC curve_NN fitting_JJ ,_, we_PRP concluded_VBD that_IN the_DT data_NNS
          best_JJS fit_VB a_DT simple_JJ one-site_JJ binding_JJ model_NN with_IN a_DT predicted_VBN
          K_NNP 
          d_SYM of_IN 0_CD ._. 37_CD nM_NN for_IN Hh-_NNP Ag_NNP 1_CD ._. 5_CD ._. This_DT K_NNP 
          d_SYM is_VBZ in_IN general_JJ agreement_NN with_IN the_DT EC_NNP 
          50_CD values_NNS observed_VBD in_IN the_DT cell-based_JJ
          assay_NN (_( 0_CD ._. 37_CD nM_NN as_IN compared_VBN to_TO 1_CD nM_NN )_) ._.
          To_TO further_VB validate_NN our_PRP$ binding_JJ results_NNS ,_, we_PRP performed_VBD
          a_DT competition_NN assay_NN using_VBG several_JJ agonist_NN derivatives_NNS
          across_IN a_DT range_NN of_IN concentrations_NNS (_( 0_CD ._. 01_CD nM_NN to_TO 1_CD μM_NN )_) ._.
          Figure_NN 7_CD cshows_NNS the_DT competition_NN curves_NNS for_IN Hh-_NNP Ag_NNP 1_CD ._. 5_CD ,_,
          Hh-_NNP Ag_NNP 1_CD ._. 3_CD ,_, Hh-_NNP Ag_NNP 1_CD ._. 2_CD ,_, Hh-_NNP Ag_NNP 1_CD ._. 1_CD ,_, and_CC the_DT
          signaling-inactive_JJ Hh-_NNP Ag_NNP 1_CD ._. 1_CD derivative_NN described_VBD above_IN ._.
          With_IN the_DT exception_NN of_IN the_DT inactive_JJ derivative_NN ,_, these_DT
          compounds_NNS all_DT compete_VBP out_RP the_DT binding_JJ of_IN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD
          (_( 0_CD ._. 4_LS nM_NN )_) to_TO the_DT Smo-containing_NNP membranes_NNS ._. These_DT data_NNS are_VBP
          best_JJS fit_VB to_TO a_DT single-binding-site_JJ competition_NN model_NN that_WDT
          predicts_VBZ the_DT following_VBG K_NNP 
          i_NNP values_NNS :_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD ,_, 0_CD ._. 52_CD nM_NN ;_: Hh-_NNP Ag_NNP
          1_CD ._. 3_CD ,_, 8_CD ._. 4_CD nM_NN ;_: Hh-_NNP Ag_NNP 1_CD ._. 2_CD ,_, 22_CD nM_NN ;_: and_CC Hh-_NNP Ag_NNP 1_CD ._. 1_CD ,_, 96_CD nM_NN ._.
          These_DT K_NNP 
          i_NNP values_NNS are_VBP in_IN general_JJ agreement_NN with_IN
          the_DT agonist_NN EC_NNP 
          50_CD values_NNS in_IN cell_NN culture_NN for_IN these_DT
          compounds_NNS ,_, with_IN the_DT exception_NN that_IN the_DT Hh-_NNP Ag_NNP 1_CD ._. 1_CD compound_NN
          is_VBZ not_RB as_IN potent_JJ in_IN signaling_VBG assays_NNS (_( EC_NNP 
          50_CD 2_CD μM_NN )_) as_IN its_PRP$ K_NNP 
          i_NNP (_( 96_CD nM_NN )_) might_MD predict_VB ._. This_DT suggests_VBZ
          an_DT uncoupling_VBG of_IN binding_JJ and_CC signaling_VBG for_IN certain_JJ
          agonists_NNS ._. Although_IN binding_JJ affinities_NNS and_CC signaling_VBG
          efficacy_NN can_MD correspond_VB for_IN certain_JJ ligand_NN /_NN receptor_NN
          complexes_NNS ,_, exceptions_NNS often_RB arise_VBP [_NN 28_CD ]_NN because_IN binding_JJ
          affinity_NN does_VBZ not_RB necessarily_RB measure_VB the_DT ability_NN of_IN a_DT
          compound_NN to_TO induce_VB an_DT active_JJ receptor_NN conformation_NN ._. As_IN a_DT
          control_NN for_IN these_DT binding_JJ studies_NNS ,_, identical_JJ competition_NN
          experiments_NNS were_VBD performed_VBN with_IN membranes_NNS from_IN cells_NNS
          transfected_JJ with_IN GFP_NNP ,_, or_CC with_IN the_DT β-adrenergic_JJ receptor_NN ._.
          No_DT specific_JJ binding_JJ or_CC apparent_JJ competition_NN was_VBD seen_VBN
          under_IN these_DT conditions_NNS (_( data_NNS not_RB shown_VBN )_) ._.
          We_PRP next_JJ compared_VBN binding_JJ of_IN KAAD-cyclopamine_NNP ,_, Cur_NNP 61414_CD
          and_CC Hh-_NNP Ag_NNP 1_CD ._. 5_CD to_TO a_DT constitutively_RB active_JJ mutant_JJ of_IN Smo_NNP
          (_( Smo_NNP act_NN )_) or_CC to_TO wild-type_JJ Smo_NNP (_( Smo_NNP wt_NN )_) ._. The_DT two_CD
          Hh-signaling_NNP antagonists_NNS ,_, KAAD-cyclopamine_NNP and_CC Cur_NNP 61414_CD ,_,
          have_VBP shown_VBN decreased_VBN potency_NN on_IN Smo_NNP act-expressing_JJ cells_NNS ,_,
          leading_VBG to_TO the_DT speculation_NN that_IN they_PRP may_MD bind_NN this_DT mutant_JJ
          form_NN of_IN Smo_NNP less_RBR well_RB than_IN the_DT wild-type_JJ form_NN [_NN 11_CD 17_CD ]_NN ._.
          We_PRP sought_VBD to_TO determine_VB whether_IN the_DT Hh_NNP agonist_NN binds_NNS Smo_NNP
          actwith_NN a_DT higher_JJR affinity_NN ,_, an_DT observation_NN seen_VBN with_IN
          certain_JJ ligands_NNS and_CC constitutively_RB active_JJ mutants_NNS of_IN
          GPCRs_NNP [_NN 29_CD ]_NN ._. To_TO perform_VB this_DT experiment_NN ,_, we_PRP isolated_VBD
          membranes_NNS from_IN cells_NNS transfected_JJ with_IN a_DT cDNA_NN construct_VB
          encoding_VBG a_DT tryptophan-to-leucine_JJ mutation_NN at_IN residue_NN 539_CD
          (_( W_NNP 539_CD L_NNP )_) of_IN murine_NN Smo_NNP ._. This_DT oncogenic_JJ mutation_NN has_VBZ been_VBN
          found_VBN in_IN human_JJ basal_NN cell_NN carcinoma_NN [_NN 3_CD ]_NN and_CC the_DT
          correspondingly_RB mutated_VBN protein_NN is_VBZ capable_JJ of_IN
          ligand-independent_JJ activation_NN of_IN the_DT Hh_NNP pathway_NN in_IN
          cell-culture_JJ assays_NNS [_NN 11_CD ]_NN ._. A_DT kinetic_JJ and_CC saturation_NN
          binding_JJ assay_NN with_IN Smo_NNP act-containing_JJ membranes_NNS showed_VBD
          that_IN this_DT mutant_JJ protein_NN binds_NNS the_DT Hh_NNP agonist_NN with_IN an_DT
          affinity_NN identical_JJ to_TO that_DT of_IN Smo_NNP wt_NN (_( data_NNS not_RB shown_VBN )_) ._.
          Using_VBG Smo_NNP act-_NN and_CC Smo_NNP wt-containing_JJ membranes_NNS ,_, we_PRP
          then_RB performed_VBD competition_NN binding_JJ studies_NNS by_IN adding_VBG
          increasing_VBG concentrations_NNS of_IN unlabeled_JJ Hh-_NNP Ag_NNP 1_CD ._. 5_CD ,_,
          KAAD-cyclopamine_NNP or_CC Cur_NNP 61414_CD in_IN the_DT presence_NN of_IN [_NN
          3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD (_( 0_CD ._. 4_LS nM_NN )_) ._. These_DT binding_JJ curves_NNS (_( Figure_NN 7_CD d_SYM )_)
          can_MD be_VB fit_VBN to_TO a_DT single-site_JJ competition_NN model_NN ._. Although_IN
          the_DT K_NNP 
          i_NNP for_IN Hh-_NNP Ag_NNP 1_CD ._. 5_CD on_IN Smo_NNP act-containing_JJ
          membranes_NNS was_VBD essentially_RB identical_JJ to_TO that_DT observed_VBD for_IN
          Smo_NNP wt-containing_JJ membranes_NNS (_( approximately_RB 0_CD ._. 5_CD nM_NN )_) ,_, the_DT K_NNP
          
          i_NNP values_NNS of_IN the_DT Hh_NNP antagonists_NNS were_VBD
          seven-fold_JJ higher_RBR on_IN the_DT Smo_NNP act-_NN compared_VBN to_TO the_DT Smo_NNP
          wt-containing_JJ membranes_NNS for_IN both_DT KAAD-cyclopamine_NNP (_( 38_CD ._. 3_LS
          nM_NN versus_CC 5_CD ._. 8_CD nM_NN )_) and_CC Cur_NNP 61414_CD (_( 309_CD nM_NN versus_CC 44_CD nM_NN )_) ._.
          These_DT results_NNS strongly_RB support_VBP the_DT model_NN ,_, initially_RB
          hypothesized_VBN for_IN cyclopamine_NN [_NN 11_CD ]_NN ,_, that_IN the_DT reduced_VBN
          potency_NN observed_VBD for_IN Hh_NNP antagonists_NNS on_IN Smo_NNP act-expressing_JJ
          cells_NNS is_VBZ directly_RB due_JJ to_TO a_DT reduced_VBN affinity_NN of_IN the_DT
          antagonist_NN for_IN the_DT mutated_VBN Smo_NNP protein_NN ._. The_DT agonist_NN ,_, on_IN
          the_DT other_JJ hand_NN ,_, would_MD be_VB predicted_VBN to_TO bind_NN to_TO a_DT site_NN on_IN
          Smo_NNP that_WDT is_VBZ not_RB affected_VBN by_IN this_DT gain-of-function_JJ Smo_NNP
          actmutation_NN ._.
        
      
      
        Discussion_NNP
        
          Models_NNP of_IN Smo-ligand_NNP interaction_NN
          To_TO interpret_VB the_DT results_NNS of_IN the_DT competition_NN binding_JJ
          studies_NNS ,_, we_PRP assume_VBP that_IN the_DT mutation_NN in_IN Smo_NNP act_NN ,_, like_IN
          those_DT in_IN constitutively_RB activate_VBP mutants_NNS of_IN other_JJ GPCRs_NNP [_NN
          29_CD ]_NN ,_, indirectly_RB influences_VBZ ligand_NN binding_JJ by_IN creating_VBG a_DT
          change_NN in_IN the_DT normal_JJ equilibrium_NN between_IN the_DT different_JJ
          conformations_NNS of_IN Smo_NNP ._. Thus_RB ,_, the_DT mutation_NN would_MD not_RB
          directly_RB influence_VB the_DT binding_JJ pocket_NN for_IN either_DT ligand_NN ._.
          A_DT simple_JJ two-state_JJ model_NN (_( Figure_NN 8_CD a_DT )_) predicts_VBZ that_IN the_DT
          agonist_NN (_( Ag_NNP ,_, green_JJ square_JJ )_) and_CC the_DT antagonist_NN (_( Ant_NNP ,_, pink_JJ
          circle_NN )_) compete_VB for_IN the_DT same_JJ site_NN on_IN Smo_NNP to_TO activate_VBP or_CC
          inactivate_NN Hh-pathway_NNP signaling_VBG ._. It_PRP also_RB suggests_VBZ that_IN
          antagonists_NNS should_MD bind_NN Smo_NNP actwith_NN a_DT lower_JJR affinity_NN than_IN
          they_PRP bind_NN Smo_NNP wt_NN ,_, while_IN the_DT agonist_NN should_MD bind_NN with_IN a_DT
          higher_JJR affinity_NN ,_, as_IN it_PRP prefers_VBZ the_DT active_JJ conformation_NN ._.
          Such_JJ a_DT model_NN cannot_NN accommodate_VB our_PRP$ observations_NNS with_IN the_DT
          gain-of-function_JJ Smo_NNP mutant_JJ ._. Thus_RB we_PRP introduce_VB a_DT ternary_JJ
          complex_JJ model_NN (_( Figure_NN 8_CD b_SYM )_) ,_, used_VBD traditionally_RB to_TO describe_VB
          the_DT behavior_NN of_IN GPCRs_NNP in_IN binding_JJ studies_NNS with_IN agonist_NN and_CC
          antagonists_NNS [_NN 31_CD ]_NN ,_, as_RB well_RB as_RB constitutively_RB active_JJ
          receptors_NNS [_NN 29_CD ]_NN ._. The_DT ternary_JJ complex_JJ model_NN for_IN Hh_NNP
          signaling_VBG suggests_VBZ that_IN there_EX are_VBP two_CD independent_JJ binding_JJ
          sites_NNS on_IN Smo_NNP wt_NN ,_, one_CD specific_JJ for_IN the_DT agonist_NN and_CC another_DT
          specific_NN for_IN antagonists_NNS ._. Binding_NNP at_IN either_DT site_NN would_MD
          decrease_VB the_DT affinity_NN for_IN interactions_NNS at_IN the_DT other_JJ site_NN
          (_( allosteric_JJ binding_JJ with_IN high_JJ negative_JJ cooperativity_NN )_) ._.
          The_DT agonist-bound_JJ form_NN represents_VBZ the_DT normal_RB activated_VBN
          state_NN ,_, while_IN the_DT antagonist-bound_JJ form_NN is_VBZ considered_VBN the_DT
          inactive_JJ conformation_NN ._. There_EX are_VBP also_RB other_JJ conformations_NNS
          that_WDT would_MD not_RB be_VB bound_VBN ,_, or_CC would_MD be_VB transiently_RB bound_VBN ,_,
          by_IN both_DT ligands_NNS ._. A_DT signaling_VBG pathway_NN coupler_NN ,_, or_CC effector_NN
          (_( in_IN blue_JJ )_) ,_, is_VBZ proposed_VBN to_TO bind_NN the_DT activated_VBN state_NN of_IN Smo_NNP
          wtso_NN as_IN to_TO generate_VB a_DT complex_JJ competent_JJ to_TO initiate_VB Hh_NNP
          signaling_VBG ._. Throughout_IN the_DT discussion_NN the_DT term_NN
          '_'' coupler_NN /_NN effector_NN '_'' is_VBZ used_VBN to_TO describe_VB an_DT unknown_JJ
          molecule_NN that_IN binds_NNS activated_VBN Smo_NNP in_IN such_JJ a_DT way_NN as_IN to_TO
          trigger_VB signal_NN transduction_NN ._. The_DT model_NN further_JJ suggests_VBZ
          that_IN the_DT Smo_NNP actprotein_NN resides_VBZ in_IN a_DT stable_JJ conformation_NN
          in_IN the_DT absence_NN of_IN agonist_NN that_WDT is_VBZ capable_JJ of_IN forming_VBG an_DT
          active_JJ coupler_NN /_NN effector_NN complex_JJ resistant_NN to_TO antagonist_NN ,_,
          but_CC not_RB agonist_NN ,_, binding_JJ ._.
          Specifically_RB ,_, our_PRP$ data_NNS suggest_VBP that_IN the_DT agonist_NN binds_NNS
          and_CC stabilizes_VBZ (_( or_CC induces_VBZ )_) an_DT active_JJ signaling_VBG state_NN of_IN
          Smo_NNP while_IN the_DT antagonists_NNS bind_NN and_CC stabilize_VB (_( or_CC induce_VB )_)
          an_DT inactive_JJ form_NN ._. Furthermore_RB ,_, the_DT gain-of-function_JJ Smo_NNP
          mutation_NN renders_NNS the_DT protein_NN less_RBR sensitive_JJ to_TO the_DT
          inhibitors_NNS ,_, presumably_RB because_IN the_DT amino-acid_JJ
          substitution_NN directly_RB stabilizes_VBZ or_CC induces_VBZ an_DT active_JJ
          conformation_NN ._. On_IN the_DT basis_NN of_IN a_DT simple_JJ two-state_JJ model_NN ,_,
          one_PRP might_MD predict_VB an_DT increased_VBN affinity_NN of_IN the_DT agonist_NN
          for_IN the_DT mutant_JJ form_NN ,_, but_CC in_IN our_PRP$ studies_NNS binding_VBG of_IN the_DT
          agonist_NN ,_, unlike_IN the_DT antagonist_NN ,_, is_VBZ not_RB affected_VBN by_IN the_DT
          activating_VBG mutation_NN ,_, suggesting_VBG that_IN a_DT more_RBR complex_JJ model_NN
          requiring_VBG two_CD binding_JJ sites_NNS and_CC perhaps_RB multiple_JJ active_JJ
          conformations_NNS is_VBZ needed_VBN to_TO account_VB for_IN the_DT observations_NNS ._.
          Thus_RB ,_, we_PRP propose_VBP a_DT variation_NN of_IN the_DT classic_JJ '_POS ternary_JJ
          complex_JJ model_NN '_'' (_( Figure_NN 8_CD )_) ,_, a_DT decades-old_JJ paradigm_NN that_WDT
          has_VBZ provided_VBN the_DT foundation_NN for_IN describing_VBG ligand_NN induced_VBD
          conformational_NN changes_NNS of_IN GPCRs_NNP [_NN 31_CD ]_NN ._.
          Briefly_NNP ,_, if_IN this_DT model_NN is_VBZ applied_VBN to_TO Hh_NNP signaling_VBG ,_, it_PRP
          proposes_VBZ that_IN ,_, firstly_RB ,_, agonist_NN and_CC antagonists_NNS act_VBP at_IN
          independent_JJ sites_NNS to_TO select_VB active_JJ and_CC inactive_JJ
          conformations_NNS of_IN Smo_NNP ;_: secondly_RB ,_, that_IN Smo_NNP engages_VBZ an_DT
          undefined_JJ coupler_NN /_NN effector_NN ,_, when_WRB it_PRP is_VBZ in_IN its_PRP$ signaling_VBG
          state_NN ;_: and_CC finally_RB ,_, that_IN the_DT gain-of-function_JJ mutant_JJ form_NN
          of_IN Smo_NNP ,_, Smo_NNP act_NN ,_, adopts_VBZ an_DT abnormal_JJ conformation_NN that_WDT
          resembles_VBZ the_DT coupler_NN /_NN effector-bound_JJ signaling_VBG state_NN of_IN
          Smo_NNP with_IN low_JJ affinity_NN for_IN antagonists_NNS but_CC normal_JJ affinity_NN
          for_IN the_DT agonist_NN ._.
        
        
          Activating_NNP Hh_NNP signaling_VBG through_IN the_DT GPCR-like_NNP Smo_NNP
          receptor_NN
          As_IN a_DT receptor_NN class_NN ,_, GPCRs_NNP are_VBP considered_VBN excellent_JJ
          drug_NN targets_NNS because_IN they_PRP are_VBP often_RB regulated_VBN through_IN
          interactions_NNS with_IN small_JJ natural_JJ ligands_NNS [_NN 32_CD 33_CD ]_NN ._.
          Specifically_RB ,_, studies_NNS of_IN classic_JJ GPCRs_NNP ,_, such_JJ as_IN the_DT
          β-adrenergic_JJ receptors_NNS ,_, show_NN that_IN in_IN the_DT absence_NN of_IN
          endogenous_JJ ligand_NN (_( agonists_NNS )_) these_DT receptors_NNS exist_VBP in_IN
          multiple_JJ interconvertible_JJ conformations_NNS that_WDT are_VBP
          predominately_RB inactive_JJ [_NN 34_CD ]_NN ._. Upon_IN exposure_NN to_TO their_PRP$
          natural_JJ ligands_NNS ,_, however_RB ,_, the_DT active_JJ receptor_NN forms_NNS are_VBP
          preferentially_RB stabilized_VBN ,_, allowing_VBG them_PRP to_TO readily_RB
          engage_VB G-_NNP protein_NN couplers_NNS and_CC to_TO create_VB
          signaling-competent_JJ complexes_NNS ._. Multiple_NNP compound_NN classes_NNS
          have_VBP been_VBN isolated_VBN on_IN the_DT basis_NN of_IN their_PRP$ ability_NN to_TO
          compete_VB for_IN the_DT binding_JJ of_IN β-adrenergic_JJ receptors_NNS by_IN
          their_PRP$ natural_JJ ligands_NNS ._. These_DT competitors_NNS can_MD mimic_VB the_DT
          natural_JJ ligand_NN activity_NN (_( agonists_NNS )_) or_CC interfere_VB with_IN it_PRP
          (_( antagonists_NNS )_) ._.
          In_IN addition_NN to_TO the_DT binding_JJ sites_NNS for_IN natural_JJ or_CC
          endogenous_JJ agonists_NNS (_( orthosteric_JJ sites_NNS )_) ,_, many_JJ GPCRs_NNP have_VBP
          also_RB been_VBN found_VBN to_TO have_VB allosteric_JJ sites_NNS [_NN 35_CD ]_NN ._. These_DT
          sites_NNS can_MD bind_NN natural_JJ ligands_NNS ,_, as_IN in_IN the_DT case_NN of_IN Zn_NNP ions_NNS
          and_CC heparin_NN for_IN the_DT dopamine_NN and_CC neurokinin_NN receptors_NNS ,_,
          respectively_RB ,_, or_CC bind_NN synthetic_JJ drugs_NNS such_JJ gallamine_NN ,_, in_IN
          the_DT case_NN of_IN the_DT muscarinic_JJ receptors_NNS [_NN 35_CD ]_NN ._. Binding_NNP of_IN
          small_JJ molecules_NNS to_TO these_DT allosteric_JJ sites_NNS can_MD modulate_VBP
          activity_NN of_IN a_DT receptor_NN without_IN directly_RB mimicking_VBG or_CC
          competing_VBG out_RP the_DT interaction_NN of_IN ligands_NNS to_TO the_DT
          orthosteric_JJ sites_NNS ._. In_IN summary_NN ,_, GPCRs_NNP have_VBP an_DT array_NN of_IN
          potential_JJ regulatory_JJ binding_JJ sites_NNS ,_, or_CC potential_JJ drug_NN
          targets_NNS ._.
          How_WRB does_VBZ Smo_NNP compare_VB with_IN other_JJ GPCRs_NNP with_IN regard_NN to_TO
          the_DT properties_NNS described_VBD above_IN ?_. Although_IN there_EX is_VBZ clear_JJ
          structural_JJ homology_NN between_IN Smo_NNP and_CC other_JJ GPCRs_NNP ,_,
          endogenous_JJ ligands_NNS have_VBP yet_RB to_TO be_VB discovered_VBN ._. Early_RB
          models_NNS of_IN Hh_NNP signaling_VBG proposed_VBD a_DT Hh-regulated_NNP Ptc-_NNP Smo_NNP
          complex_JJ that_IN directly_RB controlled_VBD the_DT conformation_NN of_IN Smo_NNP ,_,
          making_VBG endogenous_JJ ligands_NNS unnecessary_JJ ._. But_CC recent_JJ studies_NNS
          argue_VBP against_IN this_DT stoichiometric_JJ model_NN [_NN 5_CD 36_CD ]_NN ,_,
          indicating_VBG that_IN perhaps_RB natural_JJ ligands_NNS should_MD be_VB
          considered_VBN ._. Furthermore_RB ,_, regarding_VBG G-_NNP protein-effector_JJ
          coupling_NN for_IN Smo_NNP ,_, the_DT results_NNS are_VBP also_RB equivocal_NN ._.
          Although_IN no_DT compelling_JJ data_NN have_VBP been_VBN presented_VBN that_IN
          directly_RB link_NN classic_JJ G-_NNP protein_NN activation_NN [_NN 37_CD ]_NN to_TO the_DT
          canonical_JJ Hh_NNP pathway_NN involving_VBG Ci_NNP /_NN Gli_NNP stimulation_NN [_NN 2_CD ]_NN ,_,
          recent_JJ studies_NNS show_VBP that_IN under_IN certain_JJ conditions_NNS Smo_NNP can_MD
          engage_VB G-_NNP protein_NN subunits_NNS in_IN a_DT Ptc-dependent_NNP manner_NN [_NN 38_CD
          ]_NN and_CC that_IN G-_NNP protein-mediated_JJ cAMP_NN modulation_NN may_MD
          underlie_VB certain_JJ effects_NNS of_IN Hh_NNP on_IN neuronal_NN tissue_NN [_NN 39_CD ]_NN
          ._.
          Finally_RB ,_, with_IN respect_NN to_TO pharmacological_JJ properties_NNS ,_,
          our_PRP$ studies_NNS indicate_VBP that_IN Smo_NNP behaves_VBZ like_IN a_DT classic_JJ GPCR_NNP
          in_IN many_JJ regards_VBZ and_CC that_IN the_DT models_NNS used_VBN to_TO describe_VB this_DT
          large_JJ family_NN of_IN receptors_NNS can_MD be_VB applied_VBN to_TO Hh_NNP signaling_VBG
          (_( Figure_NN 8_CD )_) ._. Two_CD relatively_RB novel_NN concepts_NNS for_IN Hh_NNP
          signaling_VBG are_VBP raised_VBN by_IN these_DT GPCR_NNP models_NNS :_: firstly_RB ,_, the_DT
          importance_NN of_IN considering_VBG the_DT active_JJ Smo-coupler_NNP /_NN effector_NN
          complexes_NNS when_WRB modeling_NN pathway_NN regulation_NN ,_, and_CC secondly_RB
          the_DT potential_NN for_IN endogenous_JJ ligands_NNS in_IN the_DT regulation_NN of_IN
          Smo_NNP activity_NN ._.
        
        
          GPCR_NNP models_NNS for_IN Smo_NNP and_CC potential_JJ mechanisms_NNS of_IN Ptc_NNP
          function_NN
          A_DT recent_JJ study_NN in_IN 
          Drosophila_NNP suggested_VBD that_IN Hh_NNP
          stimulates_NNS the_DT pathway_NN via_IN Ptc_NNP degradation_NN and_CC ,_, as_IN a_DT
          result_NN ,_, Smo_NNP is_VBZ stabilized_VBN through_IN extensive_JJ
          phosphorylation_NN at_IN the_DT plasma_NN membrane_NN where_WRB it_PRP initiates_NNS
          signaling_VBG [_NN 5_CD ]_NN ._. This_DT led_VBN to_TO speculation_NN that_IN a_DT
          Ptc-regulated_NNP phosphatase_NN may_MD control_VB the_DT subcellular_NN
          distribution_NN and_CC stability_NN of_IN Smo_NNP [_NN 5_CD ]_NN ._. Although_IN
          suggestive_JJ ,_, the_DT studies_NNS in_IN 
          Drosophila_NNP did_VBD not_RB establish_VB that_DT
          phosphorylation_NN ,_, translocation_NN or_CC stabilization_NN of_IN Smo_NNP is_VBZ
          required_VBN for_IN pathway_NN stimulation_NN ._. It_PRP is_VBZ plausible_JJ that_IN
          some_DT or_CC all_DT of_IN these_DT effects_NNS on_IN Smo_NNP result_NN from_IN a_DT
          feedback_NN inhibition_NN mechanism_NN that_IN targets_VBZ the_DT activated_VBN
          Smo_NNP receptor_NN ._. Interestingly_RB ,_, while_IN we_PRP did_VBD observe_VB
          stabilization_NN of_IN Smo_NNP by_IN Hh_NNP in_IN our_PRP$ mammalian_JJ cell_NN
          experiments_NNS (_( Figure_NN 5_LS )_) ,_, we_PRP did_VBD not_RB detect_VB Smo_NNP
          phosphorylation_NN or_CC translocation_NN to_TO the_DT plasma_NN membrane_NN
          (_( data_NNS not_RB shown_VBN )_) ._. Perhaps_RB the_DT cellular_JJ (_( or_CC species_NNS )_)
          context_NN dictates_VBZ the_DT degree_NN to_TO which_WDT the_DT active_JJ
          conformations_NNS of_IN Smo_NNP are_VBP associated_VBN with_IN such_JJ changes_NNS ._.
          Thus_RB ,_, in_IN considering_VBG models_NNS of_IN Ptc_NNP function_NN based_VBN on_IN
          Hh-stimulated_NNP effects_NNS it_PRP is_VBZ important_JJ to_TO consider_VB whether_IN
          the_DT form_NN of_IN Smo_NNP that_WDT is_VBZ being_VBG observed_VBN is_VBZ the_DT active_JJ
          (_( coupler_NN /_NN effector_NN bound_VBN )_) signaling_VBG state_NN ,_, or_CC perhaps_RB a_DT
          downregulated_JJ and_CC inactive_JJ form_NN ._.
          Several_JJ potential_JJ points_NNS for_IN regulation_NN by_IN Ptc_NNP during_IN
          the_DT formation_NN of_IN a_DT Smo-coupler_NNP /_NN effector_NN complex_JJ are_VBP
          apparent_JJ in_IN a_DT ternary_JJ complex_JJ model_NN ._. The_DT ideas_NNS proposed_VBN
          for_IN the_DT 
          Drosophila_NNP system_NN ,_, in_IN which_WDT Ptc_NNP may_MD
          affect_VB the_DT levels_NNS of_IN Smo_NNP or_CC its_PRP$ subcellular_NN localization_NN ,_,
          are_VBP easily_RB accommodated_VBN ._. Ptc-induced_NNP instability_NN of_IN Smo_NNP
          protein_NN would_MD indirectly_RB reduce_VB the_DT concentration_NN of_IN an_DT
          active_JJ Smo-coupler_NNP /_NN effector_NN complex_JJ ._. Furthermore_RB ,_,
          limiting_VBG access_NN of_IN Smo_NNP to_TO its_PRP$ effector_NN through_IN targeted_VBN
          vesicle_NN trafficking_NN would_MD prevent_VB a_DT signaling-competent_JJ
          complex_NN from_IN forming_VBG ._. Alternatively_RB ,_, Ptc_NNP could_MD more_RBR
          directly_RB maintain_VB Smo_NNP in_IN an_DT inactive_JJ state_NN ._. On_IN the_DT basis_NN
          of_IN our_PRP$ studies_NNS it_PRP is_VBZ tempting_JJ to_TO speculate_VB that_IN native_JJ
          small_JJ molecules_NNS with_IN properties_NNS similar_JJ to_TO our_PRP$ agonist_NN
          and_CC antagonists_NNS act_VBP directly_RB on_IN Smo_NNP in_IN a_DT Ptc-dependent_NNP
          manner_NN ._. These_DT putative_JJ endogenous_JJ Smo_NNP modulators_NNS could_MD
          represent_VB orthosteric_JJ or_CC allosteric_JJ ligands_NNS ._.
          The_DT simplest_JJS model_NN would_MD have_VB Ptc_NNP acting_VBG catalytically_RB
          to_TO dock_NN a_DT natural_JJ antagonist_NN directly_RB onto_IN (_( or_CC remove_VB an_DT
          agonist_NN from_IN )_) Smo_NNP ._. A_DT more_RBR complex_JJ model_NN would_MD involve_VB Ptc_NNP
          restricting_VBG the_DT distribution_NN of_IN Smo_NNP such_JJ that_IN it_PRP is_VBZ
          forced_VBN into_IN compartments_NNS containing_VBG the_DT natural_JJ
          antagonists_NNS or_CC lacking_VBG the_DT natural_JJ agonists_NNS ._. Finally_RB ,_, Ptc_NNP
          could_MD control_VB the_DT distribution_NN of_IN the_DT endogenous_JJ
          small-molecule_JJ modulators_NNS themselves_PRP ._. Ptc_NNP shares_NNS sequence_NN
          homology_NN with_IN molecules_NNS associated_VBN with_IN vesicle_NN
          trafficking_NN and_CC transporter_NN activity_NN ,_, namely_RB SCAP_NNP and_CC
          NPC_NNP 1_CD [_NN 36_CD 40_CD 41_CD 42_CD ]_NN ;_: if_IN it_PRP also_RB shares_VBZ the_DT activities_NNS
          of_IN these_DT molecules_NNS ,_, as_IN suggested_VBN by_IN a_DT recent_JJ study_NN [_NN 36_CD ]_NN
          ,_, then_RB the_DT possibility_NN of_IN the_DT existence_NN of_IN endogenous_JJ Smo_NNP
          ligands_NNS that_WDT are_VBP docked_JJ via_IN Ptc_NNP should_MD be_VB explored_JJ ._.
        
        
          Therapeutic_NNP potential_NN of_IN a_DT Hh-pathway_NNP
          agonist_NN
          Various_JJ studies_NNS in_IN mammals_NNS have_VBP shown_VBN that_IN 
          Hh_NNP genes_NNS are_VBP expressed_VBN in_IN discrete_JJ
          areas_NNS of_IN the_DT adult_NN organism_NN and_CC may_MD function_VB in_IN the_DT
          normal_JJ maintenance_NN of_IN mature_VBP organ_NN systems_NNS [_NN 43_CD 44_CD 45_CD 46_CD
          ]_NN ._. In_IN addition_NN ,_, the_DT regenerative_JJ healing_NN of_IN vascular_NN and_CC
          skeletal_NN tissues_NNS following_VBG acute_JJ injuries_NNS appears_VBZ to_TO be_VB
          aided_VBN by_IN re-activating_JJ the_DT Hh-signaling_NNP cascade_NN [_NN 47_CD 48_CD ]_NN
          ._. Taken_VBN together_RB ,_, these_DT observations_NNS suggest_VBP that_IN the_DT Hh_NNP
          pathway_NN may_MD represent_VB a_DT point_NN of_IN intervention_NN for_IN
          treating_VBG certain_JJ degenerative_JJ disorders_NNS ._. Two_CD recent_JJ
          studies_NNS in_IN models_NNS of_IN Parkinson_NNP 's_POS disease_NN and_CC peripheral_JJ
          nerve_NN damage_NN support_NN this_DT claim_NN ,_, by_IN demonstrating_VBG that_DT
          pathway_NN activation_NN with_IN a_DT Hh-protein_NNP ligand_NN has_VBZ
          therapeutic_JJ value_NN [_NN 49_CD 50_CD ]_NN ._. On_IN the_DT basis_NN of_IN our_PRP$ current_JJ
          understanding_NN of_IN these_DT models_NNS and_CC the_DT specific_JJ mechanism_NN
          of_IN action_NN of_IN the_DT Hh_NNP agonists_NNS ,_, we_PRP predict_VBP that_IN an_DT
          agonist-derivative_JJ with_IN low_JJ toxicity_NN and_CC favorable_JJ
          pharmacokinetics_NNS would_MD replicate_VB these_DT positive_JJ results_NNS ._.
          As_IN a_DT drug_NN ,_, a_DT Hh_NNP agonist_NN would_MD represent_VB an_DT attractive_JJ
          alternative_NN to_TO an_DT expensive_JJ Hh-protein_NNP therapeutic_JJ ._.
          Beyond_IN the_DT economics_NNS ,_, for_IN disorders_NNS of_IN the_DT central_JJ
          nervous_JJ system_NN a_DT small_JJ molecule_NN with_IN the_DT potential_NN to_TO
          cross_VB the_DT blood-brain_JJ barrier_NN would_MD eliminate_VB the_DT need_NN
          for_IN injections_NNS directly_RB into_IN the_DT brain_NN ,_, the_DT current_JJ
          delivery_NN mode_NN for_IN central_JJ nervous_JJ system_NN protein_NN
          therapies_NNS ._.
        
      
      
        Materials_NNS and_CC methods_NNS
        
          Chemical_NN libraries_NNS and_CC medicinal_NN chemistry_NN
          The_DT compound_NN libraries_NNS used_VBN in_IN our_PRP$ screens_NNS were_VBD
          purchased_VBN from_IN a_DT number_NN of_IN commercial_JJ vendors_NNS and_CC were_VBD
          primarily_RB generated_VBN by_IN combinatorial_NN chemistry_NN
          approaches_NNS ._. The_DT Hh-agonist_NNP class_NN was_VBD isolated_VBN from_IN a_DT
          library_NN synthesized_JJ by_IN Oxford_NNP Asymmetry_NNP International_NNP ,_,
          now_RB EvotecOAI_NNP ._. The_DT derivatization_NN of_IN this_DT compound_NN class_NN
          utilized_JJ standard_JJ procedures_NNS ,_, the_DT details_NNS of_IN which_WDT will_MD
          be_VB published_VBN elsewhere_RB ._.
        
        
          Cultured_NNP cell_NN line_NN assays_NNS
          TM_NNP 3_CD and_CC C_NNP 3_CD H_NNP 10_CD T_NN 1_CD /_NN 2_CD cells_NNS (_( ATCC_NNP ;_: Manassas_NNP ,_, USA_NNP )_) were_VBD
          maintained_VBN according_VBG to_TO the_DT instructions_NNS of_IN ATCC_NNP ._. Stable_NNP
          Hh-signaling_NNP reporter_NN cell_NN lines_NNS were_VBD established_VBN by_IN G_NNP 418_CD
          selection_NN following_VBG transfection_NN with_IN a_DT luciferase_NN
          reporter_NN plasmid_NN [_NN 20_CD ]_NN containing_VBG the_DT
          neomycin-resistance_JJ gene_NN ._. Hh_NNP signaling_VBG was_VBD monitored_VBN by_IN
          plating_VBG cells_NNS at_IN 70_CD %_NN confluence_NN in_IN growth_NN medium_NN ._. After_IN
          24_CD hours_NNS the_DT cells_NNS were_VBD changed_VBN to_TO 0_CD ._. 5_CD %_NN serum-containing_JJ
          medium_NN ,_, and_CC Hh_NNP protein_NN or_CC compounds_NNS were_VBD added_VBN ;_: 24_CD hours_NNS
          later_RB the_DT cells_NNS were_VBD either_CC monitored_VBN for_IN luciferase_NN
          activity_NN using_VBG the_DT Luc-lite_NNP assay_NN kit_NN (_( Packard_NNP Instrument_NNP
          Company_NNP ,_, Meriden_NNP ,_, USA_NNP )_) or_CC harvested_VBN for_IN RNA_NNP isolation_NN
          using_VBG an_DT RNA_NNP isolation_NN kit_NN (_( Qiagen_NNP ;_: Valencia_NNP ,_, USA_NNP )_) ._. RNA_NNP
          was_VBD subjected_VBN to_TO quantitative_JJ RT-PCR_NNP analysis_NN (_( Taqman_NNP ;_:
          Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, USA_NNP )_) utilizing_VBG 
          Gli_NNP 1_CD ,_, Ptc_NNP 1_CD and_CC 
          GAPDH_NNP primers_NNS and_CC probes_NNS ._. Assays_NNP
          were_VBD run_VBN on_IN a_DT Prism_NNP 7700_CD instrument_NN (_( ABI_NNP ;_: Applied_NNP
          Biosystems_NNP )_) ._.
        
        
          Recombinant_NNP Hh_NNP protein_NN
          The_DT Hh_NNP protein_NN used_VBN in_IN the_DT studies_NNS described_VBD here_RB was_VBD
          bacterially_RB overexpressed_JJ amino-terminal_JJ human_JJ Shh_NNP
          modified_VBN at_IN its_PRP$ amino-terminal_JJ cysteine_NN by_IN an_DT octyl_NN
          maleimide_NN moiety_NN [_NN 21_CD ]_NN ._. This_DT lipophilic_JJ Shh_NNP form_NN showed_VBD
          comparable_JJ potency_NN to_TO native_JJ Shh_NNP in_IN the_DT cell-based_JJ
          reporter_NN assay_NN (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Retroviral_NNP cell_NN lines_NNS
          Mouse_NNP 
          Smo_NNP and_CC 
          Ptc_NNP 1_CD genes_NNS were_VBD introduced_VBN by_IN a_DT
          retroviral_NN approach_NN utilizing_VBG the_DT pLPCX_NN vector_NN (_( Clontech_NNP ;_:
          Palo_NNP Alto_NNP ,_, USA_NNP )_) to_TO limit_VB the_DT copy_NN number_NN per_IN cell_NN ._. Stable_NNP
          HA-Smo_NNP and_CC Ptc-_NNP GFP_NNP lines_NNS were_VBD established_VBN by_IN puromycin_NN
          selection_NN following_VBG infection_NN of_IN TM_NNP 3_CD cells_NNS with_IN the_DT
          respective_JJ retroviruses_NNS ._. TM_NNP 3_CD cells_NNS expressing_VBG both_DT
          epitope-tagged_JJ Ptc_NNP and_CC Smo_NNP were_VBD derived_VBN by_IN infecting_VBG
          first_JJ with_IN an_DT HA-Smo_NNP construct_VB and_CC subsequently_RB with_IN a_DT
          Ptc-_NNP GFP_NNP construct_VB ._. The_DT levels_NNS of_IN Ptc_NNP were_VBD relatively_RB low_JJ
          in_IN these_DT lines_NNS and_CC a_DT standard_JJ immunoprecipitation_NN
          procedure_NN followed_VBN by_IN western_JJ blotting_VBG was_VBD required_VBN to_TO
          detect_VB the_DT Ptc-_NNP GFP_NNP protein_NN ._. The_DT HA-Smo_NNP protein_NN was_VBD highly_RB
          expressed_VBN and_CC was_VBD easily_RB detected_VBN in_IN western_JJ blots_NNS of_IN
          whole_JJ cell_NN extracts_NNS ._. The_DT HA_NNP tag_NN was_VBD sub-cloned_JJ into_IN the_DT 
          Smo_NNP gene_NN so_IN that_IN it_PRP would_MD reside_VB
          immediately_RB after_IN the_DT Smo_NNP signal_NN sequence_NN ._. The_DT GFP_NNP tag_NN
          was_VBD inserted_VBN before_IN the_DT stop_NN codon_NN of_IN the_DT 
          Ptc_NNP open_JJ reading_NN frame_NN ._.
        
        
          In_IN uteroHh-signaling_JJ assays_NNS
          Generation_NNP of_IN 
          Ptc_NNP 1_CD 
          lacZ_NN ,_, 
          Shh_NNP and_CC 
          Smo_NNP mutant_JJ mice_NNS has_VBZ been_VBN described_VBN
          previously_RB [_NN 25_CD 26_CD ]_NN ._. 
          Ptc_NNP 1_CD 
          lacZ_NN /_NN +_NN mice_NNS were_VBD kindly_RB provided_VBN by_IN
          Matthew_NNP Scott_NNP ._. 
          Shh_NNP +_NN /_NN -_: and_CC 
          Smo_NNP +_NN /_NN -_: mice_NNS were_VBD kindly_RB provided_VBN by_IN
          Andrew_NNP McMahon_NNP ._. Agonist_NNP solution_NN was_VBD prepared_VBN in_IN fine_NN
          suspension_NN in_IN 0_CD ._. 5_CD %_NN methylcellulose_NN /_NN 0_CD ._. 2_LS %_NN Tween_NNP 80_CD at_IN 1_CD ._. 5_CD
          mg_NN /_NN ml_NN ._. Compound_NN was_VBD administered_VBN by_IN oral_JJ gavage_NN to_TO
          pregnant_JJ mice_NNS once_RB a_DT day_NN for_IN two_CD days_NNS at_IN 100_CD μl_NN per_IN 10_CD g_SYM
          body_NN weight_NN ._. Embryos_NNP were_VBD collected_VBN 24_CD hours_NNS later_RB ._.
          Whole-mount_NNP 
          in_IN situ_NN hybridization_NN with_IN 
          Ptc_NNP 1_CD probe_NN and_CC X-_NNP gal_NN staining_VBG for_IN
          whole-mount_JJ β-galactosidase_JJ detection_NN were_VBD performed_VBN as_IN
          described_VBN [_NN 26_CD ]_NN ._. For_IN histology_NN ,_, embryos_NNS stained_JJ with_IN
          X-_NNP gal_NN were_VBD post-fixed_JJ in_IN 4_CD %_NN paraformaldehyde_NN ,_,
          wax-embedded_JJ ,_, and_CC 20_CD μm_NN sections_NNS were_VBD prepared_VBN ._.
        
        
          Primary_JJ cerebellar_NN cultures_NNS
          Cerebellar_NNP neurons_NNS were_VBD dissected_VBN out_IN of_IN postnatal_NN
          (_( one_CD week_NN )_) rat_NN brains_NNS ,_, and_CC placed_VBD into_IN primary_JJ cell_NN
          culture_NN ._. Briefly_NNP ,_, cells_NNS were_VBD placed_VBN in_IN 96_CD -_: well_RB plates_NNS at_IN
          a_DT density_NN of_IN approximately_RB 150_CD ,_, 000_CD cells_NNS per_IN well_RB in_IN
          basal_NN medium_NN of_IN Eagle_NNP (_( Gibco_NNP ;_: Carlsbad_NNP ,_, USA_NNP )_) supplemented_JJ
          with_IN 26_CD mM_NN KCl_NNP ,_, 2_CD mM_NN glutamine_NN and_CC 10_CD %_NN calf_NN serum_NN ._.
          Treatment_NNP agents_NNS were_VBD added_VBN once_RB ,_, on_IN the_DT first_JJ day_NN of_IN
          culture_NN (_( 0_CD DIV_NNP )_) ._. Cells_NNP were_VBD left_VBN in_IN culture_NN until_IN 2_CD DIV_NNP ,_,
          when_WRB [_NN 3_CD H_NNP ]_NN -_: thymidine_NN was_VBD added_VBN for_IN 5_CD hours_NNS ._. Cells_NNP were_VBD
          then_RB lysed_JJ ,_, and_CC the_DT incorporation_NN of_IN [_NN 3_CD H_NNP ]_NN -_: thymidine_NN was_VBD
          determined_VBN by_IN scintillation_NN counting_NN ._.
        
        
          Neural_NNP plate_NN explant_NN assay_NN
          Intermediate_NNP regions_NNS of_IN the_DT open_JJ neural_NN tube_NN
          (_( i-explants_JJ )_) were_VBD dissected_VBN from_IN stage_NN 10_CD -_: 11_CD chick_NN
          embryos_NNS and_CC embedded_VBN in_IN collagen_NN gel_NN [_NN 23_CD ]_NN ._. Explants_NNP
          were_VBD cultured_JJ in_IN Ham-_NNP F_NNP 12_CD supplemented_JJ with_IN 3_CD g_SYM /_NN l_NN
          D-_NNP glucose_NN ,_, Mito_NNP Serum_NNP Extender_NNP (_( Collaborative_NNP Research_NNP ;_:
          Bedford_NNP ,_, USA_NNP )_) ,_, penicillin_NN /_NN streptomycin_NN (_( Gibco_NNP )_) ,_, 2_CD mM_NN
          L-_NNP glutamine_NN (_( Gibco_NNP )_) and_CC Hh-_NNP Ag_NNP 1_CD ._. 3_CD (_( 0_CD ._. 1_LS ,_, 1_CD ,_, 10_CD ,_, 20_CD ,_, 200_CD
          and_CC 1000_CD nM_NN prepared_VBN as_IN 1000_CD X_NNP stocks_NNS in_IN DMSO_NNP ;_: n_NN =_SYM 6_CD
          explants_NNS )_) ._. As_IN a_DT control_NN ,_, some_DT explants_NNS were_VBD cultured_JJ with_IN
          vehicle_NN alone_RB or_CC with_IN octylated_JJ Hh-_NNP N_NNP recombinant_JJ protein_NN ._.
          Cultures_NNP were_VBD fixed_VBN after_IN 22_CD hours_NNS ,_, stained_JJ with_IN mouse_NN
          monoclonal_NN antibodies_NNS against_IN Pax_NNP 7_CD ,_, MNR_NNP 2_CD or_CC rabbit_NN
          polyclonal_NN antibodies_NNS against_IN Nkx_NNP 2_CD ._. 2_LS and_CC the_DT number_NN of_IN
          immunoreactive_JJ cells_NNS per_IN explant_NN counted_VBN ._.
        
        
          Whole_JJ cell_NN /_NN immunocomplex_NN binding_JJ assay_NN
          Cultured_NNP cells_NNS -_: 70_CD %_NN confluent_NN 293_CD T_NN cells_NNS in_IN 6_CD -_: well_RB
          plates_NNS -_: were_VBD either_CC left_VBD untransfected_JJ or_CC transfected_JJ
          using_VBG Fugene_NNP 6_CD with_IN a_DT pCDNA_NN 3_CD ._. 1_LS construct_VB containing_VBG
          HA-tagged_NNP Smo_NNP or_CC v_NN 5_CD -_: epitope_NN tagged_VBN β_NN 2_CD AR_NNP (_( Invitrogen_NNP ;_:
          Carlsbad_NNP ,_, USA_NNP )_) ._. After_IN 48_CD hours_NNS cells_NNS were_VBD switched_VBN from_IN
          10_CD %_NN fetal_JJ bovine_JJ serum_NN containing_VBG DME_NNP media_NNS to_TO 0_CD ._. 5_CD %_NN FBS_NNP
          containing_VBG media_NNS supplemented_JJ with_IN either_DT 5_CD nM_NN [_NN
          3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD alone_RB or_CC 5_CD nM_NN [_NN 3_CD H_NNP ]_NN -_: agonist_NN plus_CC 5_CD μM_NN of_IN
          various_JJ competitors_NNS (_( see_VB Results_NNS )_) ._. After_IN 2_CD hours_NNS of_IN
          incubation_NN at_IN 37_CD °_NN C_NNP ,_, cells_NNS were_VBD washed_VBN one_CD time_NN with_IN PBS_NNP
          and_CC subsequently_RB lysed_JJ in_IN 0_CD ._. 5_CD ml_NN of_IN lysis_NNS /_NN wash_NN buffer_NN
          containing_VBG 1_CD %_NN NP_NNP 40_CD in_IN Tris-buffered_NNP saline_NN plus_CC an_DT
          EDTA-free_NNP protease_NN inhibitor_NN cocktail_NN (_( Roche_NNP ;_:
          Indianapolis_NNP ,_, USA_NNP )_) for_IN 20_CD minutes_NNS at_IN 4_CD °_NN C_NNP ._. Cell_NNP extracts_NNS
          were_VBD spun_VBN at_IN 14_CD ,_, 000_CD rpm_NN in_IN a_DT microcentrifuge_NN and_CC
          supernatants_NNS were_VBD incubated_JJ for_IN 40_CD -_: 60_CD minutes_NNS with_IN either_DT
          anti-_NN HA_NNP beads_NNS (_( Roche_NNP )_) or_CC anti-v_JJ 5_CD antibody_NN (_( Invitrogen_NNP )_)
          and_CC Protein_NNP A_DT beads_NNS (_( Pierce_NNP ;_: Rockford_NNP ,_, USA_NNP )_) to_TO form_VB
          immunocomplexes_NNS ._. Immunobeads_NNP were_VBD then_RB spun_VBN down_RB and_CC
          washed_VBN three_CD times_NNS with_IN 0_CD ._. 5_CD ml_NN lysis_NNS /_NN wash_NN buffer_NN per_IN
          wash_NN ._. The_DT washed_VBN pellets_NNS were_VBD then_RB resuspended_JJ in_IN SDS_NNP
          sample_NN buffer_NN and_CC combined_VBN with_IN scintillation_NN fluid_JJ ._.
          Counts_NNP per_IN minute_NN (_( cpm_NN )_) for_IN each_DT sample_NN were_VBD then_RB
          determined_VBN in_IN a_DT scintillation_NN counter_NN (_( Packard_NNP
          topcount_NN )_) ._.
        
        
          Membrane_NNP binding_JJ assays_NNS
          Membranes_NNP were_VBD prepared_VBN as_IN follows_VBZ ._. Briefly_NNP ,_,
          approximately_RB 10_CD 8_CD cells_NNS were_VBD transfected_JJ with_IN pcDNA_NN 3_CD ._. 1_CD
          constructs_NNS (_( Invitrogen_NNP )_) bearing_NN either_CC murine_NN 
          Smo_NNP (_( wild-type_JJ or_CC W_NNP 539_CD L_NNP mutant_JJ )_) ,_,
          GFP_NNP ,_, rat_NN β_NN 2_CD AR_NNP (_( Invitrogen_NNP )_) ,_, or_CC murine_NN 
          Ptc_NNP cDNAs_NNS using_VBG Fugene_NNP 6_CD (_( Roche_NNP )_) ._.
          After_IN 48_CD hours_NNS cells_NNS were_VBD harvested_VBN by_IN scraping_VBG in_IN PBS_NNP ,_,
          centrifuged_JJ at_IN 1_CD ,_, 000_CD ×_NN 
          g_SYM for_IN 10_CD minutes_NNS ,_, and_CC gently_RB
          resuspended_JJ in_IN around_IN 10_CD ml_NN of_IN a_DT 50_CD mM_NN Tris_NNP pH_NN 7_CD ._. 5_CD ,_, 250_CD
          mM_NN sucrose_NN buffer_NN containing_VBG an_DT EDTA-free_NNP protease_NN
          inhibitor_NN cocktail_NN (_( Roche_NNP )_) ._. This_DT cell_NN suspension_NN was_VBD then_RB
          placed_VBN in_IN a_DT nitrogen_NN cavitation_NN device_NN (_( Parr_NNP Instrument_NNP
          Co_NNP ,_, Moline_NNP ,_, USA_NNP )_) and_CC exposed_VBN to_TO nitrogen_NN gas_NN (_( 230_CD psi_NN )_)
          for_IN 10_CD minutes_NNS ._. Lysed_NNP cells_NNS were_VBD released_VBN from_IN the_DT device_NN
          and_CC centrifuged_JJ at_IN 20_CD ,_, 000_CD rpm_NN in_IN an_DT SS_NNP 34_CD rotor_NN for_IN 20_CD
          minutes_NNS at_IN 4_CD °_NN C_NNP ._. Supernatants_NNP were_VBD discarded_VBN and_CC the_DT
          pellets_NNS were_VBD resuspended_JJ in_IN 10_CD %_NN sucrose_NN ,_, 50_CD mM_NN Tris_NNP pH_NN
          7_CD ._. 5_CD ,_, 5_CD mM_NN MgCl_NNP ,_, 1_CD mM_NN EDTA_NNP solution_NN using_VBG three_CD 10_CD -_: second_JJ
          pulses_NNS with_IN a_DT Polytron_NNP (_( Brinkman_NNP ;_: Westbury_NNP ,_, USA_NNP )_) at_IN a_DT
          power_NN setting_VBG of_IN 12_CD ._. Using_VBG these_DT membranes_NNS ,_, filtration_NN
          binding_JJ assays_NNS were_VBD performed_VBN according_VBG to_TO previously_RB
          described_VBD protocols_NNS [_NN 28_CD ]_NN ._. To_TO reduce_VB nonspecific_JJ
          binding_JJ ,_, 96_CD -_: well_RB filtration_NN plates_NNS (_( fiberglass_NNS FB_NNP
          filters_NNS ;_: Millipore_NNP ,_, Bedford_NNP ,_, USA_NNP )_) were_VBD pre-coated_JJ as_IN
          suggested_VBN by_IN the_DT manufacturer_NN with_IN 0_CD ._. 5_CD %_NN polyethyleneimine_NN
          +_NN 0_CD ._. 1_CD %_NN BSA_NNP and_CC then_RB washed_VBN four_CD times_NNS with_IN 0_CD ._. 1_CD %_NN BSA_NNP ._.
          For_IN association_NN and_CC dissociation_NN studies_NNS ,_, membranes_NNS
          (_( 1_CD ._. 5_LS μg_NN total_JJ protein_NN )_) were_VBD incubated_JJ in_IN polypropylene_NN
          tubes_NNS with_IN 2_CD nM_NN [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD in_IN the_DT presence_NN or_CC
          absence_NN of_IN 2_CD μM_NN competitor_NN in_IN binding_JJ buffer_NN (_( 50_CD mM_NN Tris_NNP
          pH_NN 7_CD ._. 5_CD ,_, 5_CD mM_NN MgCl_NNP ,_, 1_CD mM_NN EDTA_NNP ,_, 0_CD ._. 1_CD %_NN bovine_JJ serum_NN albumin_NN )_)
          plus_CC EDTA-free_NNP protease_NN inhibitor_NN cocktail_NN (_( Roche_NNP )_) in_IN a_DT
          final_JJ volume_NN of_IN 250_CD μl_NN for_IN 1_CD -_: 26_CD hours_NNS at_IN 37_CD °_NN C_NNP ._. For_IN
          saturation_NN and_CC competition_NN binding_JJ analysis_NN ,_, membranes_NNS
          (_( 1_CD ._. 5_LS μg_NN total_JJ protein_NN )_) were_VBD incubated_JJ on_IN the_DT plates_NNS with_IN
          various_JJ concentrations_NNS of_IN the_DT [_NN 3_CD H_NNP ]_NN -_: Hh-_NNP Ag_NNP 1_CD ._. 5_CD (_( plus_CC and_CC
          minus_CC competitors_NNS )_) in_IN binding_JJ buffer_NN plus_CC EDTA-free_NNP
          protease_NN inhibitor_NN cocktail_NN (_( Roche_NNP )_) at_IN a_DT final_JJ volume_NN of_IN
          1_CD ml_NN for_IN approximately_RB 45_CD hours_NNS at_IN 37_CD °_NN C_NNP to_TO allow_VB binding_JJ
          to_TO reach_VB apparent_JJ equilibrium_NN ._. Binding_NNP reaction_NN mixtures_NNS
          (_( 0_CD ._. 2_LS ml_NN for_IN association_NN /_NN dissociation_NN studies_NNS and_CC 0_CD ._. 75_CD ml_NN
          in_IN saturation_NN and_CC competition_NN experiments_NNS )_) were_VBD then_RB
          transferred_VBN to_TO the_DT pre-coated_JJ 96_CD -_: well_RB filtration_NN plates_NNS
          (_( Millipore_NNP fiberglass_NNS FB_NNP filters_NNS )_) ,_, filtered_VBN and_CC washed_VBN
          over_IN a_DT vacuum_NN manifold_NN with_IN six_CD 300_CD μl_NN per_IN well_JJ washes_NNS of_IN
          binding_JJ buffer_NN supplemented_JJ with_IN 2_CD %_NN hydoxypropyl_NN
          cyclodextrin_NN (_( HPCD_NNP ;_: Sigma_NNP ;_: ST_NNP Louis_NNP ,_, USA_NNP )_) +_NN 0_CD ._. 1_CD %_NN BSA_NNP to_TO
          decrease_VB non-specific_JJ binding_JJ ._. Identical_NNP results_NNS were_VBD
          obtained_VBN if_IN incubations_NNS were_VBD done_VBN in_IN borosilicate_NN glass_NN
          or_CC siliconized_JJ plastic_NN tubes_NNS ._. Centrifugation_NNP assays_NNS were_VBD
          also_RB performed_VBN that_WDT replicate_VB the_DT filtration_NN assay_NN
          results_NNS (_( data_NNS not_RB shown_VBN )_) ._. Additionally_RB ,_, these_DT experiments_NNS
          showed_VBD that_IN the_DT extent_NN of_IN ligand_NN depletion_NN was_VBD less_JJR than_IN
          10_CD %_NN in_IN these_DT studies_NNS ._. Binding-kinetics_NNP experiments_NNS were_VBD
          performed_VBN similarly_RB to_TO the_DT saturation_NN and_CC competition_NN
          studies_NNS ._. All_DT binding_JJ data_NN were_VBD evaluated_VBN using_VBG a_DT
          nonlinear_NN regression_NN analysis_NN program_NN (_( Prism_NNP ;_: GraphPad_NNP ;_:
          San_NNP Diego_NNP ,_, USA_NNP )_) ._. K_NNP 
          i_NNP values_NNS were_VBD calculated_VBN using_VBG the_DT
          Cheng-_NNP Prusoff_NNP correction_NN equation_NN [_NN 28_CD ]_NN ,_, where_WRB K_NNP 
          i_NNP =_SYM IC_NNP 
          50_CD /_NN 1_CD +_NN [_NN L_NNP ]_NN /_NN K_NNP 
          d_SYM ,_, and_CC K_NNP 
          d_SYM for_IN Hh-_NNP Ag_NNP 1_CD ._. 5_CD was_VBD determined_VBN to_TO be_VB
          0_CD ._. 37_CD nM_NN by_IN the_DT saturation_NN analysis_NN ._.
        
        
          Note_VB added_VBN in_IN proof_NN
          Related_JJ results_NNS demonstrating_VBG the_DT action_NN of_IN
          cyclopamine_NN on_IN Smo_NNP have_VBP been_VBN reported_VBN by_IN Beachy_NNP and_CC
          colleagues_NNS [_NN 51_CD 52_CD ]_NN ._.
        
      
    
  
